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ABSTRACT 
 The goal of this study was to examine how dopamine (DA) and dopaminergic medications affect 
the performance of high-level visual tasks in individuals with Parkinson’s disease (PD). Various studies 
have reported that PD is associated with impairments on visual tasks known to depend on processing in 
the ventral visual pathway of the brain. Because most behavioral symptoms in PD arise from chronic 
dopamine deficiency, the author sought to investigate the role that DA played in cognitive vision. 
Accordingly, five complex visual tasks were chosen that were known to recruit processing from different 
constellations of brain areas, either in the ventral pathway or to which the ventral pathway was known 
to send projections. The tasks included discrimination of abstract objects and three-dimensional face 
stimuli, visual working memory for these same stimuli, and mental rotation of three-dimensional wire-
frame objects. An additional task, in which participants were required to discriminate between pairs of 
lines with varying orientations, was included as a control. Individuals with PD, as well as healthy age- 
and sex-matched control participants, completed all five of these tasks twice, and individuals with PD, in 
particular, were asked to complete them once on and once off of their prescribed dopaminergic 
medications. 
 The PD group performed significantly worse than the group of healthy control participants 
across all five tasks. Strikingly, the performance of individuals in the PD group did not differ significantly 
depending on their medication state. This finding indicates either that dopamine deficiency is not 
responsible for cognitive visual impairments in PD, or that the dopaminergic circuitry responsible for 
these impairments is incapable of responding to the administration of dopaminergic medication. 
Further, since all tasks, including the line orientation discrimination task, showed an effect of group, the 
results of this study are insufficient to rule out the possibility that impairments that have been reported 
elsewhere as cognitive visual deficits in PD are simply the result of deficits in more basic visual 
processing. Finally, the results of this study provide preliminary evidence that impairments of mental 
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rotation in PD are the result of impaired processing in brain regions traditionally associated with motor 
functioning. 
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CHAPTER 1. BACKGROUND 
1.1 General Introduction 
While Parkinson’s disease (PD) is most commonly associated with deficits in motor functioning, 
in many cases it is also characterized by a variety of deficits in cognition and perception. Specifically, a 
broad spectrum of visual symptoms has been observed in individuals diagnosed with PD, ranging from 
impairments in low-level vision (e.g., deficits in visual acuity and contrast sensitivity) to difficulty with 
relatively high-level visual processing (e.g., object recognition and mental object manipulation). The 
focus of this study is on symptoms that emerge from altered processing in the ventral cortical visual 
pathway and how these symptoms respond to PD treatment using dopamine precursor drugs.  
 Many of the signature effects of PD result from the death of dopaminergic neurons in the 
substantia nigra pars compacta, a structure in the basal ganglia (BG). The pathology in these neurons 
produces a profound dopamine (DA) deficiency in the areas to which they project. However, it has been 
established that dopaminergic signaling in other parts of the brain is also altered in PD, with some of 
these areas displaying disease markers similar to those observed in the substantia nigra pars compacta 
(e.g., dopaminergic cell death and deposits of misfolded α-synuclein). The fact that DA receptors have 
been discovered in a variety of regions throughout the human visual system thus lends credence to the 
view that abnormal dopaminergic transmission could be responsible for the impairments that 
individuals with PD display on visual tasks. Additionally, several pathways have been identified that 
strongly connect areas of the ventral visual pathway with structures in the BG that are known to exhibit 
DA deficiency in individuals with PD. There are thus a series of neural mechanisms by which disruption 
of DA activity in the brain could adversely affect higher vision in individuals with PD. 
 This study was designed to investigate the hypothesis that disruptions in complex object 
recognition that occur in PD are the result of abnormal dopaminergic signaling in the ventral visual 
pathway. In support of this project, there were two specific aims. The first was to determine the extent 
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to which performance of ventral pathway-dependent visual tasks varies between ON-meds and OFF-
meds states. The second was to use any observed performance differences between individuals with PD 
and their healthy counterparts to determine the location in the brain where visual processing might be 
breaking down. Accordingly, five experiments were designed to assess cognitive vision that recruits 
processing resources at various levels of this pathway. In designing the experimental tasks, 
consideration was also given to assessing visual abilities that would be important in an individual’s 
activities of daily living.  
Experiment 1 consisted of a line orientation discrimination task in which participants were 
presented with pairs of lines and asked to indicate whether the orientations of the two lines were the 
same or different. Experiment 2 consisted of object and face discrimination tasks in which participants 
were asked to indicate whether two simultaneously presented three-dimensional stimuli were the same 
or different. Experiment 3 consisted of a visual working memory task in which participants were 
presented with face and object stimuli similar to those used in Experiments 2a and b and asked to 
remember them for a short duration once the objects disappeared from the monitor. A face or object 
(from the same category as the previously studied stimuli) subsequently appear on the screen and the 
participants were asked to indicate whether that stimulus was the same as or different from the 
previously studied stimulus. Experiment 5 consisted of a mental rotation task in which participants were 
simultaneously presented with two wire-frame objects either at the same perspective or rotated in 
depth and asked to indicate whether they were the same or different. 
Participants in these experiments included 14 individuals diagnosed with idiopathic PD who 
were on a stable regimen of levodopa (a DA precursor medication) and 14 age- and sex-matched 
controls. To measure the effects of DA on visual processing, participants in the PD group performed 
each of the five visual tasks both on and off medication. Based on previous literature, the author 
expected that participants would perform all tasks better while taking their normally prescribed dosages 
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of medication, while allowing that the improvement may be larger or smaller depending on the task. A 
pilot study was conducted in which participants completed a task that aggregated the five tasks above 
into a single, more complex visual task, and performance was compared between individuals with PD 
taking their normal medication and healthy control participants of similar age. Though there was 
appreciably more variability in scores for the PD group, the group as a whole scored significantly lower 
than the group of healthy individuals on the task. 
1.2 Dopamine 
Dopamine is the most prominent of a class neurotransmitters referred to as catecholamines, a 
class of molecules characterized by their incorporation of a benzene ring with two adjacent hydroxyl 
groups (Missale et al., 1998). DA is synthesized from tyrosine, an amino acid commonly consumed in a 
normal diet or produced by the conversion of phenylalanine by enzymes in the liver and within DA 
neurons (Elsworth & Roth, 1997). Under normal circumstances, DA synthesis proceeds by uptake of 
tyrosine into DA neurons through a series of transport processes, whereupon it is converted into 
dihydroxyphenylalanine (L-DOPA or levodopa) by the enzyme tyrosine hydroxylase (Elsworth & Roth, 
1997). Importantly, conversion of tyrosine to levodopa is typically the rate-limiting step in DA synthesis, 
meaning that under normal circumstances it is less effective to increase DA levels in vivo by increasing 
tyrosine than by increasing its downstream products (Elsworth & Roth, 1997). The subsequent 
conversion of levodopa into DA is accomplished through the action of an enzyme called aromatic amino 
acid decarboxylase.  In the human brain, DA is produced primarily in two areas: the substantia nigra pars 
compacta of the BG and the ventral tegmental area of the midbrain (Vitay & Hamker, 2007). From these 
two areas, DA follows multiple pathways to diverse areas of the brain; both cortical (e.g., the medial 
prefrontal cortex) and subcortical (e.g., the thalamus and superior colliculus of the midbrain). 
The receptors for DA in the central nervous system are a group of metabotropic G protein-
coupled receptors. There are currently five recognized subtypes of DA receptors (D1 to D5) that are 
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differentiated on the basis of their DNA sequences and pharmacological properties (Missale et al., 
1998). Some classifications also differentiate between D2short and D2long, which are splice variants of the 
D2 receptor with no known differences in their pharmacological profile (Elsworth & Roth, 1997; Missale 
et al., 1998). For convenience, this taxonomy of receptor subtypes is often broken down D1-type (i.e., D1 
and D5) and D2-type (i.e., D2 to D4) on the basis of their downstream effects on adenylyl cyclase (Missale 
et al., 1998). Adenylyl cyclase is a membrane-bound protein that catalyzes the conversion of adenosine 
triphosphate to cyclic adenosine monophosphate (Sunahara et al., 1996). Cyclic adenosine 
monophasphate, in turn, is an intracellular signaling molecule that functions, among other things, to 
activate protein kinase A, which plays a role in releasing intracellular calcium stores and opening calcium 
channels in the cell membrane (Missale et al., 1998). Activation of D1-type receptors has the effect of 
increasing the activity of adenylyl cyclase, while D2-type receptors tend to decrease the activity of 
adenylyl cyclase. D2-type receptors have also been shown to increase cell hyperpolarization by 
facilitating potassium efflux from the cell (Missale et al., 1998). 
Understanding the physiology and distribution of DA receptors is essential for understanding the 
symptoms that result when DA-dependent circuitry in the brain is damaged. The next section explores 
the pathology of PD and how it arises from chronic DA depletion. 
1.3 Parkinson’s Disease 
 Much of the pathology of PD is attributed to the death of DA-producing neurons in the 
substantia nigra pars compacta (Gurevich & Gurevich, 2010). The result is a chronic DA deficiency in the 
striatum, as well as other areas of the brain that depend on DA synthesized in the substantia nigra pars 
compacta. The resulting motor symptoms are largely a complex product of dysfunction in the BG 
circuitry (though some symptoms, like resting tremor, have a more complex pathology) (Brichta, 
Greengard, & Flajolet, 2013; Gurevich & Gurevich, 2010). The rate model, which is still featured in many 
textbook descriptions of PD, characterizes this dysfunction as an imbalance of excitatory and inhibitory 
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activity between regions in the BG. The striatum (composed of the caudate and putamen) is the primary 
input structure for the BG, receiving inputs from virtually every region of the cerebral cortex and a 
variety of subcortical structures (Gerfen & Surmeier, 2011). These inputs to the striatum are principally 
glutamatergic. Glutamate is a neurotransmitter that has an excitatory effect on the spiny projection 
neurons that comprise about 90% of striatal neurons. DA plays a modulatory role on this glutamatergic 
input, either increasing or decreasing its excitatory influence depending on the whether it binds to D1 or 
D2 receptor subtypes (Gurevich & Gurevich, 2010). These two receptor subtypes are segregated in spiny 
projection neurons forming two pathways through the BG: D1 receptors are expressed exclusively by 
spiny projection neurons in the direct pathway, while D2 receptors are expressed exclusively by spiny 
projection neurons in the indirect pathway. The output structures of the BG (the globus pallidus internal 
segment and the substantia nigra pars reticulata) tonically inhibit neurons in the thalamus, and the 
direct and indirect pathways produce opposing effects on this inhibitory influence; activity in the direct 
pathway decreases thalamic inhibition, and activity in the indirect pathway increases thalamic inhibition. 
According to the rate model, when dopaminergic neurons of the substantia nigra pars compacta die, the 
resulting DA deficiency in the striatum produces an imbalance in the activity of the direct and indirect 
pathways favoring the indirect pathway, which in turn results in an increase in inhibitory input to the 
thalamus (Gurevich & Gurevich, 2010).  
In contrast to the rate model, more recent research has attributed motor symptoms in PD to 
abnormal patterns of synchronization within the BG and focused on dopaminergic inputs to the 
subthalamic nucleus instead of the striatum. In this model, a critical role for DA in healthy individuals is 
acting on the subthalamic nucleus to prevent the development of hypersynchronous activity between 
the subthalamic nucleus, globus pallidus internal segment, and globus pallidus external segment (Wilson 
& Bevan, 2011). PD has been associated with buildups of such activity, with synchronicity in different 
frequency bands associated with particular parkinsonian symptoms. Brown and colleagues (2001) have 
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shown that individuals with PD who have withdrawn from their antiparkinsonian medications develop 
characteristic patterns of hypersynchronous activity in the theta and beta bands that is predictive of 
abnormal motor activity. This abnormal activity and the corresponding symptoms subside when these 
individuals resume taking their medications. 
Irrespective of the underlying mechanisms, the resulting motor symptoms include (but are not 
limited to): bradykinesia, resting tremor, muscle rigidity, postural instability, and changes in gait 
(Gurevich & Gurevich, 2010; Brichta, Greengard, & Flajolet, 2013). Patients with PD may also experience 
a variety of non-motor symptoms, including autonomic dysfunction, gastrointestinal dysfunction, and 
sleep disorders. Individuals may also experience a spectrum of cognitive symptoms, including anxiety, 
depression, memory impairment, hallucinations, dementia, and generalized cognitive decline. 
The BG has fairly robust mechanisms to compensate for the loss of DA. In a healthy brain, the 
BG possesses an excess population of dopaminergic neurons in the substantia nigra pars compacta, so 
the death of these neurons may go largely unnoticed in the initial stages of PD (Elsworth & Roth, 1997). 
Additionally, dopaminergic neurons that are initially spared can upregulate their synthesis of DA to 
partially compensate for the death of other neurons. It has also been observed that the substantia nigra 
pars compacta can further compensate for the loss of endogenous DA by downregulating the number of 
DA reuptake sites, which allows the remaining DA to be used to greater effect in synaptic transmission 
(Elsworth & Roth, 1997). Finally, research has indicated that D1 and D2 receptors in the striatum are 
upregulated in PD. As a result of these various compensatory mechanisms, symptoms of DA depletion in 
the BG are not likely to be observed in the early stages of pathology or injury. In the case of 
parkinsonism, motor symptoms may not be observed until overall levels of striatal DA fall to near 20% of 
their initial values (Elsworth & Roth, 1997). 
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1.4 Dopaminergic Medication in PD 
The primary goal of drug therapy in PD is simply to restore DA to its normal levels by replacing it 
either with DA itself or molecules that mimic its effects (Elsworth & Roth, 1997). Accordingly, a number 
of medications have been developed that fall under the categories of either DA agonists (i.e., molecules 
that are not chemically identical to DA, but which possess similar binding properties) or DA precursors 
(i.e., molecules that can be made into DA by an individual’s own mechanisms for DA synthesis). 
1.4.1 DA Agonist Medication 
Agonist medications are used to treat symptoms of PD by mimicking the effects of DA at 
receptors that lack sufficient endogenous DA to function properly (Elsworth & Roth, 1997; Gurevich & 
Gurevich, 2010). Instead of simply replenishing the brain’s supply of biologically available DA, the 
pharmacological profiles of agonists can be manipulated to target specific symptoms of PD or optimize 
the drug’s time course (Gurevich & Gurevich, 2010).  
Agonist molecules can be engineered to selectively target the activity of specific classes of DA 
receptors, binding preferentially to D1, D2, or D3 receptors, or some combination of these (Gurevich & 
Gurevich, 2010). For instance, peroglide (trade names Permax, Prascend) functions as an agonist for D1 
and D2 receptors, while pramipexole (trade names Mirapex, Mirapexin, and Sifrol) functions as an 
agonist for D2 and D3 receptors. The ability to bind to these receptor subtypes with differing affinities is 
useful because different subtypes are associated with different symptoms in PD. For instance, while 
most of the motor symptoms in PD are associated with DA deficiency at D1 and D2 receptors, D3 
receptors have been implicated in several of the non-motor symptoms, including depression (Brichta, 
Greengard & Flajolet, 2013; Gurevich & Gurevich, 2010). Currently, most (if not all) FDA-approved 
agonist medications are D2/D3 selective (Brichta, Greengard & Flajolet, 2013). 
Additionally, agonist medications have been developed that remain at therapeutic 
concentrations in the bloodstream for significantly longer than either earlier agonist medications or 
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precursor medications. For example, cabergolide (trade name Dostinex) has a half-life of 76-100hrs 
(Gurevich & Gurevich, 2010). This is desirable feature because the dosage curves associated with 
shorter-lived drugs produce blood concentrations that are phasic and continuously variable.  This phasic 
DA activity is thought to be a major cause of dyskinesias (i.e., patterns of involuntary, purposeless 
movements). 
There are, however, several disadvantages of using DA agonist medications to treat the 
symptoms of PD. First, while short-lived agonists are implicated in the onset of dyskinesias, longer-lived 
agonists, which provide relatively continuous DA stimulation, are more likely to induce tolerance effects 
(Gurevich & Gurevich, 2010). This is particularly common in D1-selective agonists. Further, and perhaps 
more problematically, dopaminergic stimulation resulting from agonist medications occurs 
independently of the neural activity that normally triggers DA release (Gurevich & Gurevich, 2010; 
Szczypka et al., 1999). In a healthy brain, DA is released via exocytosis from a presynaptic neuron in 
response to the summed activity of inputs to that neuron. DA release in this context thus carries 
information about upstream neural activity that is subsequently conveyed to the postsynaptic neuron. 
However, DA agonists simply persist in the extracellular space until they are bound by a target DA 
receptor, so their presence is not indicative of activity in the presynaptic neuron. This means that while 
DA agonists may promote the health of neurons by providing dopaminergic stimulation otherwise 
absent in individuals with PD, these medications may be less able to support the processing for which 
these DA-dependent circuits are typically recruited. For instance, researchers have observed that 
feeding behaviors, which are severely diminished in mice and rats that have lost the ability to produce 
tyrosine hydroxylase, can be restored through the administration of levodopa (a DA precursor), but not 
through the administration of DA agonist medication (Szczypka et al., 1999). As a result of these and 
other considerations, DA agonists are typically only prescribed to patients early in the course of PD to 
delay the need for precursor medications (Gurevich & Gurevich, 2010). 
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1.4.2 DA Precursor Medication 
The goal of any dopaminergic medication used to treat the symptoms of PD is to replicate the 
effects of lost DA as closely as possible, ideally with DA. However, administration of DA itself is 
therapeutically ineffective since molecular DA is polar and thus unable cross the blood-brain barrier. In 
contrast, levodopa, the only effective DA precursor medication, contains an additional carboxylic acid 
group (removed by aromatic amino acid decarboxylase in the final step of DA synthesis) that allows it to 
pass readily through the blood-brain barrier (Elsworth & Roth, 1997). Because the conversion of tyrosine 
to levodopa is the rate-limiting step in DA synthesis, levodopa is also much more effective than tyrosine 
in producing symptom relief. A DOPA decarboxylase inhibitor (e.g., carbidopa or benzerazide) is usually 
co-administered with levodopa to inhibit its conversion to DA prior to crossing the blood-brain barrier 
(Brichta, Greengard, & Flajolet, 2013; Ball & Lee, 1977). 
Because DA is the endogenous ligand for DA receptors, levodopa essentially acts as a non-
selective agonist for all receptor subtypes (Gurevich & Gurevich, 2010). Further, because levodopa 
essentially works to restore the normal process of DA synthesis by removing the constraint of 
inadequate precursor molecules, the end-product is DA that is packaged into vesicles and released via 
exocytosis in response to action potentials in the presynaptic neuron. Thus, levodopa acts not only to 
increase net dopaminergic activity, as DA agonists do, but also acts to preserve the spike-dependent 
release of DA that may be vital to preserving DA-dependent overt behaviors (Gurevich & Gurevich, 2010; 
Szczypka et al., 1999). 
While some individuals with PD may initially rely on DA agonists to relieve the symptoms of the 
disease, levodopa is currently the only viable treatment for long-term symptom management (Gurevich 
& Gurevich, 2010). However, levodopa also has its own limitations. First of all, levodopa is less effective 
in treating some symptoms than others, with postural instability, and non-motor symptoms less likely to 
improve (Brichta, Greengard, & Flajolet, 2013). Additionally, while it is extremely effective at treating 
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symptoms during the early stages of the disease, levodopa becomes less efficacious as increasing 
numbers of DA-producing cells succumb to the disease. As a result, the dosages required to treat 
symptoms gradually increase until the symptoms eventually fail to respond. Levodopa is also relatively 
short-lived in the body, requiring frequent administration. The half-life of levodopa in the blood is 
actually only approximately 90 minutes, but its effects last appreciably longer because the product DA 
persists in synaptic vesicles until it is depleted by repeated synaptic activation (Gurevich & Gurevich, 
2010). This still means that the time between doses of levodopa is significantly shorter than that 
necessitated by long-lived DA agonists. Finally, patients eventually develop motor complications, 
typically between 5 and 7 years after beginning treatment with levodopa (Gurevich & Gurevich, 2010; 
Brichta, Greengard, & Flajolet, 2013). These include dyskinesias similar to those observed in prolonged 
treatment with short-lived agonists (though given the formal name levodopa induced dyskinesia (LID) in 
the case of precursor treatment), which occur in 40-80% individuals with PD. 
The differences between these two types of medications have important implications for 
studying the role of DA in the brain in general, and the visual symptoms in particular. For instance, 
predicting or interpreting the effects of a DA agonist requires an understanding of which receptor 
subtypes the agonist is selective for, the distribution of those receptors within brain regions of interest, 
and myriad pharmacological considerations, such as the binding affinity at each receptor subtype and 
how this compares to endogenous DA. This interpretation will be further complicated if one is examining 
behaviors that depend on spike-dependent vesicular release of DA. By contrast, levodopa results in DA 
that is produced and released by the normal cellular machinery used to produce DA in healthy 
individuals, making its effects appreciably easier to interpret. All other things being equal, levodopa 
administration will tend to normalize DA activity in areas where DA is depleted but the receptors and 
pathways remain relatively intact.  
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1.5 Visual Symptoms in PD 
 Though not as commonly associated with the disease as motor deficits, visual deficits frequently 
occur in individuals with PD. According to a questionnaire study conducted by Urwyler et al. (2014), 77% 
of individuals with PD report at least one recurring visual symptom, while 43% report two or more. 
These symptoms can range over the full spectrum of complexity in visual processing, from acuity and 
contrast sensitivity to visual navigation and face discrimination (Weil et al., 2016). What follows is a list 
of visual symptoms documented in individuals with PD and a brief description of each. These symptoms 
are specifically those that could impair processing of stationary objects by individuals with PD who 
exhibit no symptoms of dementia, so the list is not exhaustive. 
1.5.1 Abnormal Visual Evoked Potentials 
 Visual evoked potentials are the electrical activity that occurs in response to light and pattern 
stimuli measured at the scalp above the visual cortex. These changes in voltage are used as an indicator 
of visual pathway function and integrity. Patients with PD exhibit visual evoked potentials with a greater 
latency than age-matched controls (Bodis-Wollner, 1990; Bodis-Wollner & Yahr, 1978). The delay in 
visual evoked potentials can be different between the two eyes, and is shortened by administration of 
levodopa (Bodis-Wollner, 1990), suggesting a role for DA in explaining the electrophysiological 
variability. 
1.5.2 Decreased Visual Acuity 
 Visual acuity entails the ability to resolve the features of a visual stimulus while controlling for 
visual contrast (Weil et al., 2016; Jones, Donaldson, & Timmings, 1992). In one study, visual acuity was 
found to decrease by about 25% in individuals with PD compared to controls, and this deficit showed 
minimal response to treatment with levodopa (Jones, Donaldson, & Timmings, 1992). However, other 
studies have shown negligible effects of PD on visual acuity, suggesting instead that dry eyes and 
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blepharitis (i.e., inflammation of the inner eyelid) were more likely causes of individuals’ difficulty with 
visual acuity tasks (Biousse et al., 2004). 
1.5.3 Decreased Contrast Sensitivity (CS) 
 CS is defined as the ability to discriminate between a coarse object and its background while 
varying the contrast in brightness between the two (Weil et al., 2016). Because CS can vary across 
spatial frequencies in somewhat complex ways, it is typically assessed using either letters of varying 
luminance presented against a white background or using sinusoidal gratings of varying contrast and 
wavelength (Bodis-Wollner, 1990; Campbell & Maffei, 1974). CS is typically measured as a percentage of 
luminance of the stimulus compared to the luminance of the background or reference (i.e., 
100*(background luminance – stimulus luminance)/background luminance) such that a CS of 50 would 
indicate that the participant would just be able to detect the change in contrast when the stimulus was 
half as bright as its background (Regan & Neima, 1984). However, this value is often made more intuitive 
by stating it as 1/contrast threshold so that higher values indicate greater sensitivity. For example, on 
some graphs, a CS of 100 indicates that a participant could just detect a difference in contrast of 1/100 
the luminance of the background/reference.  
Individuals with PD display different CS curves than control participants. In a healthy human 
adult, the CS curve peaks at spatial frequencies near 4 cycles per degree and falls off progressively at 
both higher and lower spatial frequencies (Bodis-Wollner, 1990). In contrast, individuals with PD taking 
dopaminergic medications have curves with generally the same shape, but a significantly reduced CS at 
the 4 cycles per degree peak. The greatest difference is observed in individuals with PD in the OFF-meds 
state, for whom the CS curve peaks at 0.5 cycles per degree and falls off progressively at higher spatial 
frequencies. Put more succinctly, individuals with PD who are not currently taking their medication 
seem to display an overall decrease in CS compared to healthy controls, but relatively higher CS than 
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controls at lower spatial frequency. Further, DA medication seems to restore the shape of the curve but 
not its height.  
As with acuity, research has indicated that CS in individuals with PD can vary between the two 
eyes (Laudate et al., 2013). Research also suggests that CS deficits that accompany PD may be 
orientation-selective, such that individuals show a greater deficit in CS when sinusoidal gratings are 
oriented horizontally rather than vertically (Weil et al., 2016). 
1.5.4 Spatial Neglect 
 There have been several reports indicating that some individuals with PD experience visual 
neglect for the left visual field, but only in cases where they also report that their motor functions are 
more disrupted on their left side (Weil et al., 2016). For instance, individuals with PD who report left as 
their most affected side tend to place their mark right of center when instructed to bisect a horizontal 
line, and tend to disproportionately miss targets presented in the left visual field while performing a line 
cancellation task (Villardita et al., 1983; Laudate et al., 2013). These individuals may also show delays in 
making saccades to targets in the left hemifield and spend more time exploring the right side of a visual 
scene than the left (Weil et al., 2016; Laudate et al., 2013).  
1.5.5 Impaired Color Vision 
 PD has been linked to difficulties in color discrimination. In one study comparing individuals with 
PD to healthy controls, both groups were given the Farnsworth-Munsell 100 Hue Test (Oh et al., 2010). 
The results indicated that the PD group performed significantly worse on the 100 Hue Test overall, as 
well as the subsections specifically examining the red-green and blue-yellow color axes. These 
impairments were also found to be correlated with severity of motor symptoms. Interestingly, the 
experimental group in this study represented a fairly broad cross-section of the PD patient population, 
such that 12 of the 54 individuals had never taken medication for the condition, making the effects of 
medication on color vision difficult to discern. A variety of other studies have also found impairments in 
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color discrimination in individuals with PD, though there is conflicting evidence as to whether these 
individuals tend to show greater impairment on one color axis than the other (or whether there is a 
difference at all) (Weil et al., 2016). There is also evidence that color vision deficits in PD can be at least 
partially corrected by administration of levodopa (Büttner et al., 1994). 
1.5.6 Impaired Line Orientation Discrimination 
 Research has demonstrated that individuals with PD may have difficulty discriminating between 
lines of different orientations (Weil et al., 2016). In multiple studies, PD has been associated with 
performance on the Judgment of Line Orientation (JLO) test that is significantly lower than the 
performance of healthy control participants (Montse et al., 2001; Uc et al., 2005). This test requires 
participants to match each of a pair of target lines to one in an array of 11 reference lines, with adjacent 
lines in the array separated by 18 degrees (Montse et al., 2001). Interestingly, while participants in the 
PD group made significantly more errors than control participants overall, the PD group actually made 
fewer of what the researchers referred to as “mild intraquadrant errors” in which participants confused 
a target line with one of the reference lines 18 degrees away but in the same quadrant. Deficits in line 
orientation judgments in PD are associated with duration and severity of the disease (Weil et al., 2016). 
1.5.7 Impaired Figure-Ground Discrimination 
 Though this ability seems to have received less attention than others, PD has been associated 
with declines in performance on figure-ground discrimination tasks (Weil et al., 2016). Such tasks involve 
asking participants to identify simple figures embedded in more complex ones. In one study, Flowers 
and Robertson (1995) used a modified version of the Gottschaldt embedded figure test that allowed 
researchers to manipulate the complexity of the task, so that on some trials participants were presented 
with two possible simple figures, only one of which was actually embedded in the complex figure. Both 
groups were at ceiling on the simpler version of the task, but the PD group scored significantly lower on 
the more complex version, and scores in the PD group were correlated with age and disease severity 
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(Flowers & Robertson, 1995). However, other studies have found significant effects of PD on 
performance of an embedded figure task only in individuals with PD-related dementia and not in other 
cases (Levin et al., 1991).  
1.5.8 Impaired Depth Perception 
 Individuals with PD are more likely than their healthy counterparts to experience difficulties 
with stereopsis (Weil et al., 2016). In a study by Kim et al. (2011), 87.5% of drug-naïve PD patients were 
found to have abnormally low stereopsis according to the Titmus fly test compared to only 10% of 
control participants. Further, issues with stereopsis in drug-naïve individuals with PD have been 
correlated with significantly lower scores on a general visual perceptive/construction test (Kim et al., 
2011), and loss of grey matter in the right extrastriate visual cortex (Koh et al., 2013). It has also been 
shown that dysfunction of stereopsis in PD is associated with deficits in color vision, and is not 
significantly improved by the administration of antiparkinsonian medication (Sun et al., 2014). 
 In addition to stereopsis, depth perception in humans can also be accomplished through a series 
of monocular depth cues that do not require disparity of the image between the two retinas. To the best 
of my knowledge, no studies have examined the effects of PD on depth perception based on monocular 
cues.  
1.5.9 Impaired Object Recognition 
 Evidence is conflicting regarding the existence of object recognition deficits in PD. While some 
studies have found patients in intermediate stages of the disease have difficulty identifying overlapping 
objects (Weil et al., 2016), others have found minimal, if any, deficits in recognizing or identifying non-
face objects. A study by Laatu et al. (2004) examined the ability of individuals with PD to perform a 
broad array of visual object recognition tasks. These tasks ranged from largely visual in nature (e.g., 
determining whether a figure presented on a screen was a familiar intact object or just a series of 
scrambled features) to visual tasks with semantic components (e.g., naming an object presented on a 
16 
 
screen, or indicating whether or not an object presented on a screen is an animal). Data for all six tasks 
were collected from three different groups: cognitively deteriorated patients, cognitively preserved 
patients, and healthy controls (n = 14 for all groups). Preservation vs. deterioration was defined using 
the Mild Deterioration battery. 
 In this study, only two tasks were found where accuracy reliably distinguished the cognitively 
deteriorated group from the two control groups (Laatu et al., 2004). The first task was the Simple Word 
Discrimination task, in which participants were asked to press one key when the word “kyllä” (the 
Finnish word for “yes”) appeared on the screen, or another key when the word “ei” (the Finnish word 
for “no”) appeared on the screen. The second task was the Object Detection task, in which participants 
were asked to discriminate between drawings of familiar objects and “scrambled” drawings of those 
same objects. Differences in error rates between the three groups on all other tasks were non-
significant, and interestingly, when the Simple Word Discrimination task was run again on the same 
sample in the same study, the differences between groups were also non-significant.  
1.5.10 Impaired Face Recognition 
 Studies examining face recognition in persons with PD have found that these individuals may be 
impaired relative to healthy controls. In a study by Levin et al. (1991), researchers administered a series 
of visuospatial tasks to both groups and found that the PD group performed significantly worse on the 
Benton Facial Recognition Test (BFRT). Of the 183 individuals in the PD group, 17 were not taking any 
sort of antiparkinsonian medication, and another 13 were not taking dopaminergic medications, but 
were taking anticholinergic medications. However, because these individuals were not analyzed 
separately, this study did not provide any evidence for the effects of PD medication on task 
performance. The study did show that PD patients with dementia performed significantly worse on the 
BFRT than those without dementia. Similar results have also been found by other researchers using the 
BFRT (Pereira et al., 2009). However, at least one study using an analogous task (subtest 1 of the Florida 
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Affect Battery-revised failed to find a significant difference in performance between a PD group and a 
control group discriminating simultaneously presented photographs of faces (Jacobs et al., 1995). 
1.5.11 Impaired Facial Expression Recognition 
 A variety of studies have indicated that individuals with PD may have difficulty interpreting and 
identifying facial expressions. Jacobs et al. (1995) found that patients with PD generally perform worse 
than healthy controls at tasks that required them to analyze emotional face imagery. In this study, the 
researchers found that patients with PD had difficulty determining whether two simultaneously 
presented faces were expressing the same or different emotions. Patients with PD also performed 
worse than controls describing facial expressions associated with particular emotions, both when 
participants were asked to imagine faces with the target expression and when they were actually 
presented with images of the target emotional expression. 
 Other studies have found that PD disproportionately impacts perception of negative emotional 
expressions. These include, but may not be limited to, fear, sadness, and disgust (Weil et al., 2016). 
Recognition of emotional expression by individuals with PD has been found to improve upon 
administration of antiparkinsonian medication (Sprengelmeyer et al., 2003). 
1.5.12 Impaired Visual Working Memory (VWM) 
 At least in some instances, PD may be associated with deficits in being able to retain items in 
VWM. In one study, Pereira et al. (2009) administered Warrington’s recognition memory test for faces 
to both individuals with PD (but not dementia) and healthy control participants to examine their ability 
to remember novel faces for short durations. Specifically, participants were presented with 50 
photographs of novel male faces and asked to rate whether they found these faces pleasant or not. 
Immediately after participants gave their ratings the same photograph would return to the screen along 
with a distractor face, and participants were asked to indicate which face they had seen previously. 
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Analysis revealed that participants with PD scored significantly lower on average on this task than their 
healthy counterparts  
Additionally, DA medication in PD has been shown to play a role in working memory more 
generally. In a study by Lange et al. (1992), a group of 10 individuals were tested using a series of 
working memory tasks for which individuals with PD have previously demonstrated significant 
impairment. In this study, these tasks were administered both while participants were taking their 
normal dopaminergic medications and following controlled withdrawal. The researchers found that 
withdrawal from medication tended to exacerbate WM impairments, but did so selectively for WM tasks 
known to recruit circuits in the frontal lobe. 
1.5.13 Impaired Mental Rotation 
 Several studies have indicated that PD is associated with impairments of mental rotation of 
objects, though interestingly the exact effect may depend on the axis of rotation. A study by Lee et al. 
(1998) used a classic set of wire-frame stimuli developed by Shepard and Metzler (1971) to examine the 
mental rotation abilities of individuals with PD (Lee et al., 1998). Two stimuli were presented 
simultaneously that were either identical or that varied slightly in one of their components. Additionally, 
the stimuli could be presented either at the same angle or at angles that differed by between 20 and 
180 degrees at increments of 20 degrees. Over the course of two experiments, participants were 
instructed to indicate whether the two simultaneously presented figures were the same or different, 
irrespective of the angle between them. 
In the first experiment the figures were rotated in depth (i.e., about the vertical axis), and the 
researchers observed an interaction such that the PD group made significantly more errors than the 
control group, but only when the stimuli were the same (i.e., when participants falsely identified the 
stimuli as “different”) (Lee, et al., 1998). Further, the rate of errors by the PD group to stimuli that were 
the same increased as the angle between them increased, such that when stimuli were rotated more 
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than 140 degrees with respect to each other, participants actually performed appreciably worse than 
chance. Specifically, when the stimuli were the same but rotated 180 relative to one another, the error 
rate for the PD group was approximately 80%. By contrast, in the second experiment the stimuli were 
rotated in the picture plane. In this case, the PD group produced significantly greater reactions times 
than the control group, but did not make significantly more errors, irrespective of stimulus type.  
Other researchers using different paradigms have failed to observe deficits in mental rotation 
related to PD. For instance, Ogden, Growdon, and Corkin (1990) presented participants with 2 
dimensional shapes and instructed them to indicate which of an array of 3 dimensional objects 
represented the former shape folded along indicated seams. The error rates for a PD group and a 
control group were both well above floor, but not significantly different.  
Several of the symptoms considered above correspond to visual processes associated with 
ventral visual pathway function, which is the focus of the present study. The following section contains 
an examination of the ventral visual pathway and the ways in which its functioning might be affected by 
the pathology of PD.  
1.6 Possible Mechanisms for Visual Symptoms in PD 
There are at least three possible avenues by which abnormal DA signaling in the brain could lead 
to impairments of cognitive vision. First, previously characterized PD pathology in the BG could lead to 
performance deficits on visual tasks that recruit processing resources from the striatum. Second, PD 
may lead to impaired dopaminergic signaling in areas of the visual system itself that are required for 
performance on visual tasks (i.e., without any direct involvement of the BG). Lastly, DA activity within 
the visual system or other critical areas, which are relatively spared by the effects of PD (at least in the 
early stages), may be disrupted by the dopaminergic medication used to treat the disease. Each of these 
possibilities is considered below, along with a fourth possibility that is not subject to the influence of 
fluctuations in dopaminergic activity. 
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1.6.1 Model 1: Visual Symptoms May Be Related to Damage in the BG 
 The striatum in the BG has the highest expression of DA receptor mRNA (both D1 and D2) of any 
region in the human brain (Hurd, Suzuki, & Sedvall, 2001) and dysfunction of dopaminergic signaling in 
the striatum is believed to be the principal cause of the majority of motor and cognitive deficits in PD 
(Gurevich & Gurevich, 2010). Thus, to the extent that visual tasks recruit processing resources from the 
BG, it is likely that the DA depletion in the BG associated with PD would lead to deficits in visual 
processing. There are several major pathways projecting from the ventral visual pathway to the striatum 
whose activity might be affected by the pathology of PD in the BG. 
 The occipitotemporo-neostriatal pathway sends projections from almost every region of the 
ventral pathway to the striatum of the BG (Kravitz et al., 2013). Moreover, the projections are 
topographically organized, such that V2 and V4 project to the most caudal regions of the caudate 
nucleus while progressively more rostral areas of the ventral pathway project to progressively more 
rostral sites in the caudate tail and the caudoventral putamen. There is potential for information from 
this pathway to influence processing in myriad areas of the brain through the series of corticostriatal 
loops that comprise the BG. The areas of the striatum innervated by this pathway also send a projection 
back to the ventral visual pathway via the substantia nigra pars reticulata and thalamus, providing the 
opportunity for recurrent processing between the BG and ventral visual pathway (Kravitz et al., 2013; 
Seger, 2013). 
 The occipitotemporo-ventral striatum pathway originates entirely from the anterior 
inferotemporal cortex (IT) and terminates in the ventral striatum, both in the nucleus accumbens and 
the olfactory tubercle (Kravitz et al., 2013). The ventral striatum, in turn, projects to a variety of cortical 
and subcortical areas, including lateral prefrontal cortex (PFC), orbitofrontal cortex, amygdala, and 
hippocampus. This pathway thus provides another opportunity for relatively high-level visual 
information from the ventral visual pathway to influence processing across diverse areas of the brain.  
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Given the connectivity between the ventral visual pathway and the BG, it is not surprising that 
some researchers have at times conjectured that the BG actually subserves high-level visual processing 
(Middleton & Strick, 1996). Further evidence came from a lesion study by Divac and colleagues (1967), 
which showed that lesioning of the caudate tail in macaques impaired performance on a visual 
discrimination task. However, more recent research indicates that these pathways between the BG and 
the ventral visual pathway are actually involved in more cognitive aspects of processing visual stimuli. 
Specifically, the occipitotemporo-neostriatal pathway has been implicated in learning visual associations 
based on reward, such that damage does not lead to impairments in fundamental visual discrimination 
of stimuli (Fernandez-Ruiz et al., 2001). In contrast, the occipitotemporo-ventral striatum pathway has 
been implicated in the assignment of value to stimuli (Kravitz et al., 2013). This finding has been 
supported by imaging studies of humans indicating that the ventral striatum shows selective activation 
for rewarded outcomes (Liu, X et al., 2011). Given this evidence, PD pathology in the BG seems less likely 
to disrupt visual object discrimination as such, but would be more likely to disrupt learning of object 
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associations and values. By extension, supplementing depleted DA in the BG with a DA precursor 
medication would seem unlikely to improve impaired performance on object discrimination tasks. 
1.6.2 Model 2: Visual Symptoms May Be Related to Impaired DA Signaling in the Visual Pathways 
 DA receptors have been observed in a wide range of visual areas of the human brain. In terms of 
regions involved in object identification and recognition, these include a variety of areas from the retina 
(Djamgoz & Wagner, 1992) to regions of the PFC involved in manipulating representations of visual 
objects (Hurd, Suzuki, & Sedvall, 2001).  
In human visual processing, visual information travels from the retina of each eye to V1 (also 
known as the primary visual cortex or striate cortex) via the lateral geniculate nuclei (LGN) of the 
thalamus (Callaway, 2005). Studies have shown that the retina (Bodis-Wollner, 1990), as well as the LGN 
and V1 (Hurd, Suzuki, & Sedvall, 2001), contain dopaminergic circuitry, indicating that DA plays a 
significant role in very early visual processing. 
 In the human retina, D2 receptors have been identified in both the inner nuclear layer 
(containing the cell bodies of the bipolar, horizontal, and amacrine cells) as well as the outer plexiform 
layer (containing the synapses between the horizontal cells of the inner nuclear layer and the 
photoreceptors of the outer nuclear layer) (Bodis-Wolner, 1990; Demb & Singer, 2015). DA in the retina 
is released by amacrine cells and a population of interplexiform cells, and the influence of this DA on the 
cells of the inner nuclear layer and outer plexiform layer is thought to contribute to light adaptation and 
establishing the center-surround organization of retinal receptive fields that facilitates edge detection 
(Bodis-Wollner, 1990; Demb & Singer, 2015). These functions have been proposed as mechanisms by 
which pathology of the DA circuitry in the retina might lead to loss of CS and delayed visual evoked 
potentials (Bodis-Wollner, 1990). And, indeed, PD pathology has been observed in the inner retinal layer 
of the eyes, including misfolded and phosphorylated α-synuclein (Weil et al., 2016). To the best of the 
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author’s knowledge, there has been no research to date characterizing any relationship between the 
dopaminergic circuitry of the retina and that of the substantia nigra pars compacta. 
In a study by Hurd, Suzuki, and Sedvall (2001), researchers used in situ hybridization to examine 
the distribution of D1 and D2 receptor mRNA throughout the entire human brain using whole-
hemisphere sections. They found that both receptor subtypes are expressed fairly broadly throughout 
the brain, with D2 receptors having higher expression overall, while D1 receptors had appreciably greater 
expression in the cerebral cortex. Of more relevance to vision in particular, moderate to high levels of D2 
receptor mRNA were identified in the LGN, while moderate to high levels of D1 receptor mRNA were 
identified in the infragranular layers (i.e., layers V and VI) of V1. It would thus be tempting to predict 
that DA depletion in these areas might lead to deficits in perception of visual features to which the 
retinal fields of the LGN and V1 are most responsive (e.g., bars of light of particular lengths, either 
stationary or moving perpendicular to their long axes) (Hubel & Wiesel, 1959). However, the location of 
DA receptors in the infragranular layers of V1 is particularly striking due to the arrangement of the 
circuitry between V1 and LGN. Specifically, fibers projecting from the LGN (an area containing relatively 
high expression of D2 mRNA) innervate layer IV of V1, but the neurons in layers VI of V1 (i.e., the layer 
containing relatively high expression of D1 mRNA) actually project back to the LGN (Cudeiro & Sillito, 
2006). Further, the number of corticothalamic fibers projecting from V1 back to the LGN is more than an 
order of magnitude larger than the feedforward connections between the LGN to V1, such that the 
corticothalamic projection actually constitutes the single largest input to the LGN. Models of the 
recurrent processing between these two regions of the brain have predicted that this loop might 
contribute to visual processes ranging from brightness perception and stereopsis to perception of 
illusory contours and perceptual grouping (Cudeiro & Sillito, 2006). The state of knowledge concerning 
the interaction between the LGN and V1 and its functions, as well as precise location and role of DA 
24 
 
receptors in this circuitry, would make any predictions arising from DA depletion and/or replacement in 
this area speculative at best. 
The ventral pathway emerges from V1 and proceeds through the preoccipital gyrus, the inferior 
temporal gyrus, and the ventral temporal pole (Kravitz et al., 2013). While D1 and D2 mRNA is not 
expressed in these regions at levels that approach those in the BG, the signal from these regions 
observed by Hurd et al. (2001) was still moderately strong, as it was for much of the cortex. This raises 
the possibility that dysfunctional DA signaling could lead to deficits in ventral pathway function that 
could produce deficits in high-level processing similar to those described previously (e.g., face and 
object recognition, as well as others that depend on processing resources in IT). However, given the 
broad distribution of DA receptor mRNA in the cortex (disproportionately D1 mRNA), it is hard to see DA-
specific pathology producing visual processing deficits without similarly affecting cortical processing 
more broadly. 
Finally, the ventral pathway sends a projection – known as the occipitotemporo-ventrolateral 
prefrontal pathway – from anterior aspects of the superior temporal sulcus to the ventrolateral PFC 
(Kravitz et al., 2013). The ventrolateral PFC is thought to play a significant role in visual processing that 
recruits working memory functions, and ventrolateral PFC cells in the monkey display strong object 
selectivity. Damage to this area in monkeys has been shown to lead to deficits in object working 
memory, while similar damage in humans impairs working memory for faces. These observations make 
ventrolateral PFC dysfunction a likely source of several of the PD-related visual deficits discussed 
previously (e.g., performance decrements on mental rotation and VWM tasks). However, the levels of 
DA receptor mRNA recorded by Hurd et al. in this region were among the lowest recorded anywhere in 
the cortex. So while these regions may be important for visual object-related tasks requiring working 
memory, it is not clear what effects, if any, modulation of DA in individuals with PD might have on these 
tasks. 
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1.6.3 Model 3: Visual Symptoms May Be Related to Excess DA from DA Precursor Medication  
 The possibility exists that at least some visual symptoms in PD that are customarily attributed to 
pathology of the disease itself are actually the result of the medications used to treat it. In a review 
conducted by Poletti and Bonuccelli (2013), a number of tasks were identified for which performance by 
PD patients significantly decreased while they were taking their normal levodopa regimen compared to 
when they were off of their medication. These tasks included probabilistic reversal learning, distractor 
resistance, probabilistic classification learning, and an episodic memory task. Additionally, patients who 
took DA agonists instead of levodopa have also displayed performance deficits on cognitive tasks that 
decreased when they abstained from medication. Specifically, individuals with PD taking pramipexole 
were shown to perform worse on tasks involving attention, set-shifting, and verbal short-term memory 
while they were on their medication, and individuals taking apomorphine performed worse on a VWM 
task while taking their normal medication (Poletti & Bonuccelli, 2013). 
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In some cases, performance on tasks that initially appear relatively similar can respond in 
opposing ways to dopaminergic medication in individuals with PD. In one study, patients who had been 
prescribed levodopa to treat PD were asked to complete two reward-based learning tasks that varied 
slightly in their learning rules (Graef et al., 2010). In the Instrumental Learning task, reward 
contingencies remained constant throughout the task such that each stimulus was associated with a 
particular probability of reward that never changed throughout the task. In the Reversal Learning task, 
the reward contingencies for each stimulus were changed once a participant reached a criterion of 75% 
accuracy on the task, requiring the participant to learn a new set of reward contingencies to maximize 
their performance. Importantly, participants completed each task twice: once while taking their regular 
prescribed dosage of levodopa, and once after abstaining from the drug for at least 12 hours (treatment 
orders of drug conditions were counterbalanced to prevent confounding drug and condition order 
effects).  The results showed that participants performed significantly better in instrumental learning 
task (i.e., under constant reward contingencies) when they were on medication than when they 
abstained, but participants performed significantly better in the reversal learning task (i.e., under 
variable reward contingencies) when they were off medication than when they took their prescribed 
dosage. 
One explanation for the inconsistent effects of dopaminergic medication on cognitive task 
performance is that the loss of DA in the striatum is progressive, beginning in the head of the caudate 
nucleus and moving caudally over time (Cools, 2006; Poletti & Bonuccelli, 2013). Dopamine depletion in 
the rostral caudate would initially affect connections between the dorsolateral striatum and the 
dorsolateral PFC, the dorsomedial globus pallidus, and the thalamus (Poletti & Bonuccelli, 2013). As the 
loss of DA advanced caudally, it would also affect connections between the ventromedial striatum, the 
orbitofronto cortex, the dorsomedial globus pallidus, and the thalamus (Poletti & Bonuccelli, 2013). 
Consistent with this anatomical progression, cognitive tasks relying on reciprocal connectivity between 
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the BG and the dorsolateral PFC (e.g., task switching,) have been shown to suffer disproportionately 
early in the course of PD, while those relying on reciprocal connectivity between the BG and 
orbitofronto cortex (e.g., probabilistic reversal learning) are relatively spared (Cools et al., 2003). Indeed, 
early cognitive symptoms of PD are often said to resemble those of patients with frontal lobe lesions 
(Cools et al., 2003; Muslimović et al., 2005). The reason for the detrimental effects of DA on these tasks, 
is has been suggested, is that dopaminergic medication, while producing therapeutic effects on DA-
depleted circuitry, actually has a deleterious effect on the DA circuitry that is spared early in the disease 
course (Cools, 2006; Poletti & Bonuccelli, 2013). This model is referred to as the “Dopamine Overdose 
Hypothesis”, and predicts that the tasks that are impaired by the administration of dopaminergic 
medication are those that recruit circuitry that has not yet been compromised by the pathology of PD. 
The implications of these studies for the effects of levodopa administration on ventral visual 
pathway function are unclear. First of all, to the extent that levodopa has been shown to affect vision at 
all, its effects tend to be either beneficial or negligible. As previously mentioned, abnormal VEP latency 
(Bodis-Wollner, 1990), as well as deficits in acuity (Jones, Donaldson, & Timmings, 1992), contrast 
sensitivity (Bodis-Wollner, 1990), color vision (Büttner et al., 1994), stereopsis (Sun et al., 2014), and 
recognition of facial expressions (Sprengelmeyer et al., 2003) all seem to improve in individuals with PD 
when they are on dopaminergic medications compared to when they are unmedicated. On the other 
hand, the contribution of the ventral visual pathway to performance of these visual tasks is likely to be 
relatively minimal. Abnormalities in visual evoked potentials, acuity, CS, and stereopsis can all 
potentially be attributed to well-documented pathology of dopaminergic circuits in the retina, while 
impaired recognition of facial expressions has been attributed by some to pathology in subcortical 
structures (e.g., the amygdala) (Weil et al., 2016). One possible exception is color vision, which has 
shown to improve following administration of dopaminergic medication (Büttner et al., 1994). 
Nonetheless, the effects of levodopa remain to be tested on a variety of visual deficits that can readily 
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be attributed to ventral visual pathway function, and so it is still an open question as to what effect 
levodopa will have on these tasks. To the extent than any of these visual symptoms in PD are caused or 
exacerbated by levodopa administration, withdrawal from levodopa may improve performance on these 
tasks. 
1.6.4 Model 4: Visual Symptoms May Be Related to More General Brain Pathology 
 While DA depletion is certainly a principal contributor to much of the pathology in PD that 
affects observable behavior, protein aggregates and cell death also play a role that increases over the 
course of the disease. It is not entirely clear how much atrophy occurs in the early stages of PD. For 
instance, Menke et al. (2014) did not observe any significant difference in grey matter volume between 
a group of cognitively normal individuals with PD and a group of healthy controls using conventional 
magnetic resonance imaging (MRI) techniques, though a decrease in grey matter was observed using a 
more sensitive technique known as vertex-wise analysis, which analyzes the shape of subcortical 
structures. In contrast, a study by Burton et al. (2004) also used MRI and identified significantly 
decreased grey matter volume in the frontal lobe in a cognitively normal PD group. Another study by 
Pereira et al. (2009) reported that individuals with PD (but not dementia) showed significantly decreased 
grey matter in areas of the frontal, temporal and parietal lobes, as well as bilateral cerebellum and 
limbic structures. For individuals with mild cognitive impairment, decreases in grey matter have also 
been observed in a variety of cortical areas across the frontal, temporal, and parietal lobes, as well as 
several subcortical structures (e.g., the amygdala, hippocampus, and right putamen) (Melzer et al., 
2011). Those with advanced PD who have developed dementia display more severe losses in grey 
matter in these areas, but also show decreased volume in other regions, including the posterior 
cingulate gyrus and the occipital cortex (Melzer et al., 2011; Burton et al., 2004).  
 Thus, it may be that impairments in ventral pathway-dependent visual processing in individuals 
with PD occur not because of a partially reversible depletion of DA, but because the circuitry of the 
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visual pathways has irreversibly broken down. Several studies have reported correlations between visual 
deficits in PD and decreased grey matter density in specific areas of the brain. For instance, Koh et al. 
(2013) found that abnormal stereopsis in individuals with PD was associated with significantly reduced 
grey matter in Brodmann area 18 in the extrastriate visual cortex.  Another study by Pereira et al. (2009) 
tested individuals with PD on their ability to perform Benton’s facial recognition test, a visual form 
discrimination test, and a recognition memory test for faces, and compared participants’ scores on these 
tasks to variations in grey matter density. Decreased performance by individuals with PD on the face 
recognition task was associated with decreased grey matter volume in the fusiform gyrus, 
parahippocampus, middle occipital gyrus, and inferior frontal gyrus. In contrast, decreased performance 
on the visual form discrimination task was associated with grey matter losses in the superior parietal 
and occipital lobes, as well as in the inferior and middle frontal gyri. Finally, decreased performance on 
the test of memory for faces was associated with grey matter losses in the right parahippocampus.  
 In these cases, visual processing deficits in PD may arise simply because the circuitry on which 
they depend has been destroyed. Even if these circuits once depended on DA for their function, 
replenishing depleted DA in regions of the brain where dopaminergic circuitry has severely atrophied 
obviously cannot be expected to provide a meaningful therapeutic effect.  
 One way to adjudicate among these various possibilities is to examine the effects of DA on visual 
tasks known to recruit processing from different regions within the ventral visual pathway, as well as 
regions to which it projects. However, since the experience of individuals with PD withdrawing from 
their antiparkinsonian medications tends to be unpleasant, it was important to first develop a visual task 
that could demonstrate performance differences between healthy individuals and individuals with PD. If 
no such differences existed, or if the task used was incapable of capturing them, it would be ethically 
dubious to proceed with a study likely to cause appreciable discomfort to participants. The researcher 
therefore designed and conducted a pilot study comparing the performance of healthy individuals and 
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individuals with PD in the ON-meds state on a visual task that required multiple perceptual processing 
steps. 
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CHAPTER 2: PILOT STUDY 
2.1 Design and Justification 
 The purpose of the current study is to examine the effects of levodopa, a DA precursor 
medication used in the treatment of symptoms of PD, on the performance of visual tasks that depend 
on the ventral visual pathway. To that end, the preceding review has been intended to firmly establish 
that such deficits in visual tasks exist in individuals with PD, and that there are scientifically established 
avenues by which DA might be expected to modulate performance on these tasks, either by improving 
or impairing it.  
Testing the prediction that administration of levodopa will alter ventral pathway-dependent 
function requires identifying tasks whose performance provides a meaningful indicator of that function. 
Face recognition, object recognition, and mental rotation of objects are all processes that are 
characteristic of ventral pathway function, and all three are known to be impaired in individuals with PD. 
Thus, a pilot test was devised using novel objects and faces as stimuli. Participants were tested on their 
ability to study these stimuli, remember them over a brief delay, and discriminate between studied and 
unstudied stimuli (of the same category), either at the learned angle or a novel angle. Task performance 
was then compared between a group of individuals with PD and healthy individuals of similar age.  
If individuals in the PD group performed significantly worse on this task than those in the control 
group, then this would support the idea that ventral visual processing is impaired in individuals with PD, 
and that at least one processing step in this task was sufficient to demonstrate that impairment. 
2.2 Methods 
2.2.1 Participants 
Participants recruited for this study consisted of 5 healthy older adults (ages 67 to 85 yrs.), and 7 
older adults (ages 69 to 84 yrs.) who had received a clinical diagnosis of Parkinson’s disease. To be 
eligible for participation in this study, individuals with PD were required to be between the ages of 40-85 
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yrs., to have been taking the same PD medication for at least the past 30 days, to score at least 24 on 
the Mini Mental Status Exam, and to score no greater than 18 on the Beck Depression Inventory. One 
participant had to be removed from the final analysis because the individual could not state with 
certainty that they had been on the same medication for a full 30 days (and because this individual fell 
asleep repeatedly during the object recognition task). Thus, data from only 6 of the 7 participants 
recruited for the PD group were analyzed. 
2.2.2 Object Recognition Task 
The object recognition task consisted of 64 trials presented on a computer monitor. Each trial 
consisted of a Study period and a Test period. During the Study period (2500 ms), participants were 
asked to study and remember an object presented on the screen. The study period was followed by a 
brief delay (3000 ms), and then a Test period in which participants were asked to indicate whether an 
object that subsequently appeared on the screen was the same as or different than the object 
presented in the Study period. There was no time limit on the Test period, so the second object 
remained on the screen until participants responded. Responses were made through a standard 
keyboard, with participants instructed to press “z” if they believed the object was the same, and “m” if 
they believed the objects were different.  
The stimuli used in each trial were either monochromatic 3-dimensional renderings of faces or 
abstract 3-dimensional figures composed of seven cylinders of varying lengths connected end-to-end. 
The latter were referred to as “tube sculptures” in the instructions issued to participants. Thus, there 
were two different object conditions: a Face condition (32 trials) and a Tube condition (32 trials). 
In addition to the two object conditions, there were also two study conditions and two test conditions. 
The two study conditions were Stationary, in which each stimulus remained at the 0-degree orientation 
for the duration of the 2500 ms Study period, and Variable, in which each stimulus was cycled through a 
series of three different orientations (0 degrees, 40 degrees, 0 degrees, -40 degrees, and back to 0 
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degrees) presented for 500 ms each. The two test conditions were Original, in which the stimulus 
presented in the Test period was presented in the 0-degree position (i.e., an orientation presented in 
the Study period), and Novel, in which the stimulus presented in the Test period was presented at either 
+/- 20-degrees of rotation about the z-axis (i.e., an orientation not presented in the Study period). 
 
2.2.2.1 Faces 
Examples of the Face stimuli used in this experiment can be seen in Figure 3. To create each 
stimulus image, a series of photographs of human faces was first collected from Google images. All 
photographs were required to have closed mouths and neutral expressions. Some of the photographs 
used were of famous individuals, but the subsequent rendering process obscured their identities so that 
they were unrecognizable by the time they were presented as stimuli. Half of these photos were of men 
and half were of women. For each gender category, photographs were further selected on the basis of 
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race so that 25% of the photos were of Asian individuals, 25% were of Black individuals, 25% of the 
photos were of Caucasian individuals, and 25% were of Latino/Latina individuals. While the rendering 
process likely obscured any features that would have facilitated visual categorization into demographic 
groups, effort was made to ensure that the initial images represented a broad (though incomplete) cross 
section of individuals. 
Once these photos were collected, a computer program called FaceGen (https://facegen.com/) 
was used to render each face onto a 3-dimensional head. This process removed all of the color and hair 
from the faces so that each could be distinguished only through inspection of its structural features. The 
process also allowed all heads to be rendered at a constant height, so that they could not be 
distinguished on the basis of how closely their edges came to the border of the screen.  
Once these 3-dimensional heads were rendered, they were exported as .obj files and opened in Blender 
(http://www.blender.org), a freeware 3D art program that allowed for precise manipulation of the 
heads in 3-dimensional space. This allowed for the creation of images of each head rotated about the 
vertical axis 0-degrees (i.e., directly facing the observer), +/- 20-degrees, and +/- 40-degrees, for a total 
of 5 images produced from each initial photograph. 
2.2.2.2 Tube sculptures 
Examples of the Tube Sculpture stimuli used in this experiment can also be seen in Figure 3. 
These objects were based on those used by Logothetis, Pauls, and Poggio (1995). Each was created as a 
series of eight points that would fall within the surface of a cylinder measuring 20 units high and 10 units 
in diameter (i.e., all were equidistant from a central, vertical axis). These eight points were connected in 
serial order to form a figure composed of seven line segments. The set of points was constrained so that 
line segments formed by connecting them would be constrained to between 4 and 10 units, and angles 
formed by adjacent segments were constrained to between 90- and 120-degrees.  Once each set of 
points was calculated and drawn using a Python script, they were rejected if the resulting figures 
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contained line segments that intersected, or if the figures were not sufficiently tall (i.e., at least 16 units 
on the z-axis). Once each set of points had been finalized, they were rendered in MatLab2016b 
(https://www.mathworks.com/products/matlab.html). Use of MatLab allowed not only for more 
complex 3-dimensional rendering of the Tube Sculptures, but also allowed for precise rotation of each 
object about the vertical axis. As with Face objects, images were made of each Tube Objects from five 
angles spaced 20-degrees apart.  
2.2.3 Procedure 
 Upon arriving for the data collection, the researcher provided participants with a brief 
description of the study, after which written informed consent was obtained. All participants completed 
the Mini Mental Status Exam, at which point participants in the healthy control group proceeded 
directly to the object recognition task. Participants in the PD group also completed the Beck Depression 
Inventory and the Unified Parkinson’s Disease Rating Scale (UPDRS) prior to completing the object 
recognition task. The UPDRS is an assessment of the extent to which PD symptoms interfere with an 
individual’s projects of daily living, and is used as a measure of disease progression. The UPDRS took 
approximately 30 minutes to complete, after which individuals in the PD group proceeded to complete 
the object recognition task. The time needed to complete the object recognition task ranged from 15-20 
minutes. Following the completion of all tasks, participants were debriefed.  
2.3 Results 
 Scores between the two groups were analyzed using a simple between-subjects T-test. Overall, 
the PD group scored significantly lower on the task (M = 66.41%, S.E = 4.52%) than the HOA group (M = 
84.69%, S.E. = 2.59%), t(9)= 3.312, p=.009. Given the relatively small sample size, and the somewhat 
preliminary nature of the pilot study, within-subjects T-tests were also used to assess the effectiveness 
of the within-subjects manipulations. Within the PD group, no significant difference in performance was 
observed between object type conditions (tube sculptures vs. faces, p = .34). Adding multiple training 
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views also did not seem to make a difference (p = .53), nor was there an observed disadvantage for 
offsetting the probe stimulus by 20 degrees (p = .73). Given that there might also have been some 
effects of congruency in the 3D manipulation conditions (e.g., participants might have been expected to 
perform better on trials with an offset probe when they had been trained on multiple views of the 
object), a 2 (training condition: single view vs. multiview) x 2 (probe condition:  no rotation vs. 20-degree 
rotation) ANOVA was performed to analyze these contingencies in the PD group. However, in comparing 
scores across conditions no reliable interaction was observed (p = .574). 
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2.4 Discussion 
 The results of the pilot study are consistent with the hypothesis that individuals with PD are 
more likely to have difficulty with face and object discrimination than their healthy counterparts. Even 
with a relatively small sample, some combination of the manipulations in this task was capable of 
modulating performance in processing of novel object and face stimuli. The efficacy of the 3D 
manipulations in this task was considerably less impressive. This may have had something to do with the 
angles at which objects were rotated. For this task, objects were presented at a maximum rotation 
about the vertical axis of 40 degrees. This angle was chosen as an upper limit because it was the largest 
rotation that was observed not to disrupt the structural descriptions of the faces or occlude their 
features. However, studies that have found effects of 3D rotation in individuals with PD have tended to 
use a much larger degree of angular rotation (e.g., Lee et al., 1998). It may therefore be advisable in 
future studies of mental rotation in individuals with PD to utilize a paradigm that more closely resembles 
one that has been shown to produce a significant effect. 
 Additionally, it should be noted that several individuals in the PD condition mentioned 
experiencing fatigue during the object recognition task. While it is unclear whether this issue 
contributed to any performance deficits on this task, it might be prudent in the future to consider 
splitting up any visual task into blocks that can be separated by short breaks. 
 Because the visual task used in the pilot study was capable of capturing performance differences 
between individuals with PD and their matched counterparts, the researcher proceeded to the main 
study using a series of visual tasks based on processing steps involved in the pilot task. The goal was to 
determine which steps had resulted in performance deficits observed in the PD group. By testing these 
steps individually and measuring the effects of DA on performance, the researcher sought to determine 
what neural mechanisms might underlie any observed deficits, as well as any role of dopaminergic 
medication in mitigating or exacerbating these deficits. 
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CHAPTER 3: DESIGN AND JUSTIFICATION FOR CURRENT STUDY 
 
3.1 General 
This study was organized around two aims. The first aim was to determine the extent to which 
the performance of individuals with PD completing ventral pathway-dependent visual tasks varies 
between ON-meds and OFF-meds states. While individuals with PD have been shown here and 
elsewhere to have greater difficulty performing such tasks than their healthy counterparts, the extent to 
which this was a direct result of chronic DA deficiency was unknown. Also unknown was the extent to 
which such task performance could be modulated by the administration of levodopa. The author sought 
to make these determinations by examining the visual processes that comprised the pilot study 
individually, both following withdrawal of all antiparkinsonian medication and immediately following 
administration of levodopa. To contextualize the magnitude of any observed change in performance 
between medication conditions, performance on each task was be compared to that of a control group 
of healthy older adults. 
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 The second aim was to use any observed medication-related performance differences on these 
tasks to determine the location in the brain where visual processing might be breaking down. While it is 
known that processing in the ventral visual pathway does not occur in a serial, hierarchical fashion, it is 
also known that processing resources are recruited from different visual areas as object processing 
becomes increasingly complex. Thus, it was hoped that differences in performance by the PD group on 
visual tasks of increasing complexity might be diagnostic of which abilities and ventral visual areas were 
affected in PD and which, if any, are relatively spared.  
 Given the forgoing research in which deficits on various lower visual tasks were exhibited in 
individuals with PD and subsequently improved under the influence of dopaminergic medication, the 
author hypothesized that participants in the PD group would perform better in the ON-meds condition 
across all five experiments. Also, since little was previously known concerning how PD might affect the 
visual areas recruited for these tasks, and since there was no a priori reason to believe that performance 
on any of the visual tasks would benefit disproportionately from administration of levodopa, the author 
hypothesized that no single brain area would be found to be responsible for performance deficits by the 
PD group on these five tasks. 
3.2 Design Modifications from Pilot Study 
 The experience of running the pilot study, and subsequent feedback from colleagues, informed 
several changes to the procedure of the five main experiments in this study. First, multiple participants 
in the pilot study struggled with fatigue during the 64-trial visual task. Because the protocol for the main 
study used similar tasks over a much longer span of time, all five of the experimental tasks in the main 
study were broken up into four blocks separated by short breaks. At each break, text appeared on the 
computer monitor indicating the percentage of the task the participant had completed (25%, 50%, or 
75%) and encouraging participants to take a moment to collect themselves and engage in physical 
activity or conversation before continuing if they felt it would be helpful. 
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 Several other modifications were made to help participants adjust to the testing environment, 
as well as minimize stress and confusion. First, a task was added at the beginning of the Morning testing 
session for the sole purpose of familiarizing participants with the format of the computerized visual 
tasks. During this acclimation task, participants were asked to make the same sort of same/different 
judgments that they would be asked to make for all of the experimental tasks, but the stimuli that 
participants were asked to distinguish were photographs of families and landscapes that were highly 
discriminable. Participants used the same key mapping during the acclimation task as they would for all 
the experimental tasks throughout the day (“m” for same and “z” for different, or vice versa) in the hope 
that this would become habituated and minimize the attention required for proper responding (see 
section 3.4 for a full description of the procedure for the acclimation task). All participants completed 
the acclimation task irrespective of their experimental group. To further minimize stress and confusion 
in responding to the experimental tasks, the appropriate key mapping was displayed at the top of the 
screen every time a participant was asked to make a response. This was the case for both the 
acclimation task and all experimental tasks. 
 For the main study, the short form of the Geriatric Depression Scale replaced the Beck 
Depression Inventory as an indicator of depression in participants. While both scales are in common use 
and scores on both are strongly correlated, the Geriatric Depression Scale was designed specifically for 
individuals in the age range targeted for the current study, and there is evidence that the Geriatric 
Depression Scale is easier for older adults to complete (Olin et al., 1992). In addition, some research 
indicates that the Geriatric Depression Scale produces more accurate responses particularly in older 
women owing to its omission of questions related to sexual interest (Jefferson, Powers, & Pope, 2008). 
 Part of the goal for the main study was to determine what impaired perceptual process or 
processes was/were responsible for the relatively poor performance by individuals with PD on the pilot 
task. While previous research has indicated individuals with PD may display impairments on complex 
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visual discriminations and VWM of the type required to complete the pilot task (see section 1.5), the 
results of the pilot study could also be explained by individuals with PD having deficits in more 
fundamental visual processes, such as poor contrast sensitivity, or simply poor visual acuity. As such, 
Experiment 1 consisted of a line orientation discrimination task to assess the extent to which processes 
other than complex object discrimination might have caused the deficits observed in the pilot task. 
Additionally, a requirement has been added that all participants across groups must have been judged 
to have normal or corrected-to-normal visual acuity as determined by an eye appointment within the 
preceding year. 
 As noted previously, the rotation manipulation in the pilot study failed to produce any effect on 
task performance either for individuals with PD or their healthy counterparts. However, multiple other 
studies have documented impairments of mental rotation in individuals with PD. Examining the ability of 
individuals with PD to perform mental rotation, and the effect of levodopa on this process, therefore 
necessitated employing a different 3D manipulation. To this end, Experiment 5 is largely a replication of 
Lee et al. (1998), with the exceptions that a) the stimulus set used is one more recently developed by 
Ganis and Kievit (2015) and b) individuals with PD were tested in both ON-meds and OFF-meds states. 
 Finally, there is a body of research indicating that human vision is especially well-adapted for 
symmetry detection, so much so that this process may occur rapidly at a preattentional level (see 
Wagemans, 1997 for a review). Experiments 2a, 2b and 3 of the main study involve the simultaneous 
presentation of complex visual stimuli and ask participants to judge whether they are the same or 
different, and there is thus a risk that participants’ performance will be driven by preattentional 
processing if “same” stimuli presented side-by-side create a symmetrical display, while “different” 
stimuli do not. It should be noted that the stimuli used in these tasks are such that there is minimal risk 
of identical objects producing a symmetrical visual display: the face stimuli from Experiment 2b are 
adapted from real photographic images and unlikely to be perfectly symmetrical themselves, and 
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consequently unlikely to create a perfectly symmetrical visual display when placed side-by-side on the 
screen. Accidental display symmetry is even less likely for the abstract objects used in Experiments 2a 
and Experiment 3, since the methods for creating these stimuli tend to yield objects that are themselves 
highly asymmetrical. However, because the stimulus sets for Experiments 2a and 2b had not been tested 
in other studies and the author desired to show that performance on these tasks was a result of the 
visual processing of objects and not a heuristic judgment of symmetry, the stimuli presented on each 
trial of these two tasks were slightly offset from one another in the vertical direction. This should have 
disrupted any accidental display symmetry that might have resulted from the simultaneous presentation 
of two identical objects. 
3.3 Participants 
Given the efficacy of levodopa in treating a variety of PD symptoms, it is not uncommon to find 
studies testing the effects of drug modulation that use patient samples of fewer than 10 individuals (Lee 
et al., 1998; Stegemöller Simuni, & MacKinnon, 2009). It is also notable that significant between-subjects 
effects were observed in the pilot study using a sample of only six individuals with PD and five healthy 
older adults. To add a margin of safety, it was decided that the study would target 15 healthy older 
adults and 15 older adults who have received a clinical diagnosis of PD.  
To be eligible for participation in this study, all individuals were required to be between 60 and 
80 years of age and to have either normal or corrected-to-normal vision as determined by an eye 
appointment within the last 12 months. Additionally, individuals in the PD condition were required to 
have received a formal clinical diagnosis of the condition. The latter were further required to be 
currently taking levodopa as part of their treatment regimen, and their dosage must have been stable 
for at least the last 30 days. Accordingly, the researcher recruited 15 individuals for the PD condition. 
One of these individuals mentioned during the course of the study that she was receiving deep-brain 
stimulation as part of her treatment regimen, and her data have not been included in the analysis, 
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leaving 14 in the PD condition. Subsequently, 14 healthy individuals who were age (+/- 3 years) and 
gender matched to individuals in the PD group were recruited. Thus, the final sample included 14 
individuals with a diagnosis of PD (Age: M = 71.1, S.D. = 5.8; 5 Female, 9 Male) and 14 healthy individuals 
(Age: M = 70.1, S.D. = 4.9; 5 Female, 9 Male). The two groups did not differ significantly in age (p = .81) 
or years of education (p = .51). 
Individuals in the PD group were recruited in part from a laboratory database of known 
volunteers and in part from reaching out to a number of support groups across the state of Iowa. 
Individuals in the HOA group were recruited in part from the same laboratory database and in part from 
general community outreach. 
 
3.4 General Procedure for Experiments 
 All materials and procedures were approved by the Institutional Review Board (IRB) (see 
Appendix A). Upon arriving for the data collection, the researcher provided participants with a brief 
description of the study, after which written informed consent was obtained. All participants completed 
the Mini Mental Status Exam and the Geriatric Depression Scale.  
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Participants in both the Healthy Older Adult (HOA) group and the Parkinson’s disease (PD) group 
completed the study in two sessions during the same day: A Morning session and an Afternoon session. 
Depending on the preference and transportation needs of the participant, the study was conducted 
either at the Neurophysiology Lab at Iowa State University, at a medical facility or community center 
proximate to the participant’s residence, or at the participant’s residence. Both groups completed all 
five visual tasks once during each session, and lunch was provided by the experimenter in between the 
two sessions. 
3.4.1 Procedure for PD Group 
All participants in this group were provided with a copy of the Informed Consent Document 
prior to the day of testing, either via mail, email, or in person, and asked to read through and sign the 
document once they felt they adequately understood what was involved, but prior to the day of testing. 
It was important that informed consent be obtained prior to withdrawal from any medications to ensure 
that all participants were in a normal, maximally healthy state of mind. On the morning of the data 
collection, participants in the PD group were asked to abstain from their morning dose of all 
antiparkinsonian medications. However, they were instructed to take any other medications they had 
been currently prescribed as normal. Upon arriving at the testing location, all members of this group 
were conveyed to the testing room via a wheelchair to mitigate the possibility of falls or injuries. Once in 
the testing room, the experimenter reviewed and verified the signed Informed Consent Document and 
personally verified that all participants met the a priori exclusion criteria. Participants were then asked 
to complete the Mini Mental Status Exam and Geriatric Depression Scale forms, confirming that they 
also met these exclusion criteria. All participants in the PD group then completed the motor portion of 
the UPDRS to serve as an index of their PD symptoms in an OFF-meds condition. This and all portions of 
the UPDRS in this study were administered by the author, who was trained and certified in the 
procedure by the Movement Disorder Society. 
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Immediately following this task, participants completed a computerized task designed to help 
them acclimate to their surroundings and familiarize them with the format of the experimental tasks. 
Each of the 20 trials in the acclimation task consisted simply of the simultaneous presentation of two 
photographic images on a computer screen, which were either family photographs or landscapes with 
no people present. Participants were asked to indicate whether the two images were the same or 
different by pressing one of two keys on a standard keyboard. Images in the Same condition were 
always identical, and images in the Different condition always consisted of one family photo and one 
landscape to maximize ease of judgement. Participants were given as long as they needed to make a 
decision on each trial, and the keys that corresponded to “same” and “different” on the keyboard 
(either z or m) remained constant for all tasks for the remainder of the study. 
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Once they had completed the acclimation task, participants in the PD group proceeded to 
complete all five of the computerized visual tasks. Due to the number of trials in Experiment 1, this task 
was divided into three parts with each administered separately. The three parts of the Experiment 1 task 
and the other four experiment tasks were all pooled and administered in random order. 
Following completion of the first round of experimental tasks, the Morning session ended 
participants in the PD group were asked to take 1.5 times their standard dose of levodopa while 
continuing to abstain from any other antiparkinsonian medications. This procedure is common in the 
literature as a means bringing individuals with PD back up to standard therapeutic levels of their 
medication after abstention, and was endorsed by Dr. Michael S. Okun, the Chair of Neurology at the 
University of Florida and Medical Director of the Parkinson’s Foundation, following consultation. 
Participants were also given the opportunity to take any additional non-antiparkinsonian medications 
they required during this time. Following the administration of medication, the experimenter provided 
participants with lunch from their choice of local venues. 
Following lunch, and at least one hour following administration of levodopa, participants began 
the Afternoon session of the study. To this end, participants again completed all of the visual tasks from 
the morning session, save for the Acclimation task. All tasks were again administered in random order. 
Once all tasks had been completed, participants completed the full version of the UPDRS. The overall 
score was used as an index of their overall disease progression, while the score on the motor portion 
was compared to their score from the morning as an index of the effect of their levodopa medication. 
Once participants had completed the UPDRS, the Afternoon session was complete and participants were 
debriefed. 
3.4.2 Procedure for the HOA Group 
The procedure for individuals in the HOA group was identical to the PD group with the following 
exceptions: 
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1. Participants were not required to sign the Informed Consent Document prior to arrival at the 
testing location, since no withdrawal from medication was required. 
2. Participants were not required to be conveyed from the parking lot to the testing room in a 
wheelchair. 
3. Participants did not complete any portion of the UPDRS during either testing session. 
4. There was no formal requirement that any participant take any medication during the course of 
the study, though they were allowed to take any medication they customarily took (none did). 
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CHAPTER 4: RESULTS OF LEVODOPA ADMINISTRATION: 
Participants in the PD group for this study were asked to abstain from their morning dose of 
antiparkinsonian medications on the day of the study, and were asked to take 1.5 times their optimal 
dose of levodopa during the break between sessions to return to therapeutic levels of the drug. The 
motor portion of the UPDRS was administered at the beginning of the Morning session and at the end of 
the Afternoon session and was used as an index of how the resulting change in DA levels affected 
participants’ PD symptoms. This subscale consists of 33 items on which participants may receive a score 
between 0 (does not display symptom) and 4 (most severe), for a possible (but highly improbable) score 
of 132. Thus, a higher score indicates worse symptoms. 
The results of this experimental manipulation are shown in Fig. 7. A within subjects t-test 
showed a significant effect of levodopa administration, t = -3.08, p < .01, with symptoms being more 
severe in the morning (M = 26.86, SD = 13.83) than in the afternoon (M = 22.12, SD = 11.38). However, 
as Fig. 7 shows, there was appreciable variation between individuals, with two participants showing 
modestly worse symptoms during the Afternoon session.  
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CHAPTER 5: EXPERIMENT 1 
5.1 Background 
While the human visual system is known to rely on recursive rather than strictly serial 
processing, it is still acknowledged that there are higher levels of visual processing that require 
successful processing at lower levels to perform their function (Gilbert & Li, 2013; Vidyasagar & Eysel, 
2015). The progressive nature of visual processing can thus complicate visual studies because individuals 
may perform equally poorly on a complex task (e.g., face discrimination) in cases where they have 
deficits in lower visual processing (e.g., macular degeneration) and cases where they have deficits in 
higher processing (e.g., prosopagnosia).  
As noted above, multiple studies have found that individuals with PD tend to perform worse on 
line discrimination tasks than their healthy counterparts (Montse et al., 2001; Uc et al., 2003). 
Additionally, the comparatively poorer performance on the pilot task by individuals in the PD group 
could be equally well explained by damage to one or more of the myriad lower visual processing steps 
on which this task is likely to depend. It also has not escaped notice that broad array of visual deficits 
observed in individuals with PD make the idea of a more fundamental common cause intuitively 
appealing. Therefore, in addition to the requirement that all participants in this study possess normal or 
corrected-to-normal vision, this study included a line orientation discrimination task to assess 
participants’ ability to differentiate between more basic visual features. While the ability of individuals 
with PD to perform this task as well as their healthy counterparts would not prove that poor 
performance by the former on complex visual tasks was not due to deficits in lower-order visual 
processing, an inability of the former to perform this task as well as healthy control participants would 
need to be considered when interpreting the results of more complex tasks. For instance, if individuals 
with PD performed significantly worse than healthy individuals on the mental rotation task, but a similar 
group effect was found on the line orientation task and the effect sizes were comparable, then it would 
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be problematic to conclude that the observed deficit in mental rotation was a mental rotation 
impairment per se. Rather, it could simply be the downstream effect of a more basic visual impairment. 
 
 The most commonly referenced line discrimination task in the current literature is the Benton 
Judgment of Line Orientation (JLO) Test (Ska, Poissant, & Joanette, 1990; Montse et al., 2001; Tranel et 
al., 2009) (see Fig. 9). In this task, participants view an array of 11 reference lines with adjacent lines 
rotated by 18 degrees (Benton, Varney, & Hamsher, 1978). They are then shown two target lines of 
shorter length on a different page and asked to indicate the two reference lines rotated at the same 
angles as the target lines. Participants are given an unlimited amount of time to make this judgment. 
While this task has been used in a variety of studies examining the effects of PD (e.g., Levin et al., 1991; 
Finton, Lucas, Graff-Radford, & Uitti, 1998; Montse et al., 2001), the judgment participants were asked 
to make in the JLO differed sufficiently from that of the pilot study for the present research that the 
creating of a new task was desirable. Specifically, the JLO is a matching task requiring participants to 
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select a similarly oriented line from an array of alternatives, whereas the present study is aimed at 
investigating discriminability. The JLO also requires participants to make two correct judgments (one for 
each target line) for a trial to be scored as correct, which complicates the interpretation of results. 
 While this experiment was intended to inform the interpretation of other experiments in this 
study, any evidence of a line orientation discrimination deficit in individuals with PD by itself is difficult 
to interpret from a neuropsychological standpoint. It has long been known that there are cells located in 
the primary visual cortex of cats (Hubel & Wiesel, 1959) and non-human primates (Hubel & Wiesel, 
1968) that respond selectively to bars of light and edges of particular sizes and orientations. However, 
more recent research has shown that cells earlier in the visual systems of many mammals display signs 
of orientation selectivity, including some LGN and retinal ganglion cells (Vidyasagar & Eysel, 2015; Nath 
& Schwartz, 2016). To complicate matters further, an imaging study conducted by Tranel et al. (2009) 
examining the performance of patients with brain lesions on the JLO revealed that the damaged areas 
most associated with diminished task performance were the right angular gyrus and areas of the dorsal 
visual stream, including the posterior region of the supramarginal nucleus. So, while it has been shown 
that performance on the JLO improves in individuals with PD following pallidotomy (Junqué et al., 1999), 
the neural underpinnings of any differences in line orientation discrimination between individuals with 
PD and healthy individuals, as well as between individuals with PD in an ON-meds vs. OFF-meds state, is 
beyond the scope of this study. The goal of this experiment was simply to determine the extent to which 
any observed impairment on higher visual tasks could be reasonably attributed to dysfunction in higher 
visual areas. 
5.2 Methods 
5.2.1 Participants 
 All participants from the study sample completed this experiment and were included in the 
analysis. See section 3.3 for details concerning sample characteristics and recruitment methods. 
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5.2.2 Stimuli 
 Stimuli consisted of pairs of white line segments set against a black background. The longer 
dimension of each line segment covered three degrees of visual angle, and the gap between pairs of 
segments was also three degrees. On each trial, one line segment was rotated in the picture plane 
between 0 and 90 degrees from horizontal by some multiple of 10 (e.g., 10 degrees, 20 degrees, 30 
degrees, etc.). On half of the trials, the second line segment was at the same angle as the first (i.e., 
rotated at 0 degrees with respect to the first segment) while on the other half of trials the second line 
segment was rotated between 10 and 90 degrees with respect to the first, again by some multiple of 10 
degrees. 
5.2.3 Procedure 
 During this task, participants saw two line segments appear simultaneously on a computer 
monitor, and were asked to indicate whether the two segments were positioned at the same 
orientation. The task consisted of 180 trials, but was administered in three installments of 60 trials each 
to minimize any effects of fatigue or proactive interference.  
 Each trial began with a blank screen that persisted for one second, followed by the simultaneous 
presentation of two white horizontally aligned line segments. Half of all participants pressed the “z” key 
if they believed that the two lines were at the same angle on the screen and pressed the “m” key if they 
believed the two lines were at different angles, while for half of participants this mapping was reversed. 
There was no pre-set time limit on each trial, so the stimuli remained on the screen until the participants 
responded. Each of the three installments of this task was divided into blocks of 15 trials, between 
which the experiment paused and encourage participants to take a break for as long as they liked prior 
to resuming.   
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5.3 Results 
The effects of PD pathology and levodopa treatment on line orientation discrimination were 
examined using a 2 (Group: PD vs. HOA) x 2 (Session: Morning vs. Afternoon) ANOVA. The results of this 
analysis are shown in Fig. 10. There was a main effect of Group, F(1,26) = 12.74, p = .001, η2p = .329., 
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with the HOA group (M = 98.45%, S.E. = .88%) scoring higher on the task than the PD group (M = 94.01%, 
S.E. = .88%). There was also a main effect of Session, F(1,26), p = .01, η2p = .223, with participants across 
groups performing modestly better in the Morning (M = 96.63%, S.E = .64%) than the Afternoon (M = 
95.83%, S.E. = .64%) session. No other effects or interactions rose to the level of significance. 
 
 
To analyze the kinds of errors made by the two groups, an additional analysis was conducted to 
examine participants’ performance at different angles of rotation. To simplify this analysis and its 
interpretation, trials in which the lines were positioned at 0 degrees relative rotation were omitted, and 
the remaining rotation angles were grouped into Small (10, 20, and 30 degrees), Medium (40, 50 and 60 
degrees) and Large (70, 80, and 90 degrees), resulting in a 2 (Group: PD vs. HOA) x 2 (Session: Morning 
vs. Afternoon) x 3 (Angle: Small, Medium, and Large) mixed factorial ANOVA. This analysis again 
revealed a main effect of Group, F(1,26) = 13.45, p = .001, η2p = .341, with the HOA group (M = 97.78%, 
S.E. = .96%) making more correct judgments than the PD group (M = 92.78%, S.E. = .96%). There was 
also a main effect of Session, F(1,26) = 5.24, p = .03, η2p = .168, with participants across groups 
performing better in the morning (M = 95.91%, S.E. = .65%) than the afternoon (M = 94.64%, S.E. = 
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.81%). Additionally, this analysis revealed a main effect of Angle, F(2,52) = 23.491, p < .001, η2p = .475, 
with participants across groups performing worse on trials with Small angles of rotation (M = 89.58%, 
S.E. = 1.69%) than either Medium (M = 98.63%, S.E. = .37%) or Large (M = 97.62%, S.E. = .70%) rotations. 
The interaction between Angle and Group was also significant, F(2,52) = 4.34, p = .02, η2p = .143. 
Specifically, while both groups performed more poorly on Small than Medium trials, the PD group also 
performed more poorly on Small than Large trials, while no corresponding difference was observed for 
the HOA group. 
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 The relationship between levodopa administration and task performance for individuals in the 
PD group was also assessed by calculating difference scores for the line discrimination task and the 
motor portion of the UPDRS between sessions and performing a correlational analysis. The correlation 
did not reach significance either when all participants were analyzed (p = .94) or when participants 
whose UPDRS motor scores did not improve for the afternoon session were removed (p = .52). Finally, 
overall performance by the PD group during the Afternoon session (i.e., when they were ON-meds) was 
examined for any relationship with their disease progression. There was a trend toward a negative 
correlation between task score and UPDRS score, but this association did not reach the level of 
significance (p = .05), and no correlation was observed between task score and years since disease onset 
(p = .88).  
5.4 Discussion 
The goal of this experiment was to examine the possibility that the results observed in the pilot 
study, and by extension other complex visual tasks, could be explained by more basic visual deficits in 
individuals with PD. The results of Experiment 1 indicate that some of the of the observed differences 
between individuals with PD and their healthy counterparts may be accounted for by deficits in basic 
feature discrimination. The difference in performance between the PD and HOA groups was significant 
for this task, and a probable ceiling effect for both groups may have masked the full extent of this 
difference. This result is consistent with the findings of several studies indicating that individuals with PD 
performed worse than their healthy counterparts on the Benton JLO task (Montse et al., 2001; Finton et 
al., 1998).  
 Aim 1 of the current study was to examine any effect of DA and dopaminergic medications on 
visual processing. Given the design of Experiment 1, such an effect would most likely appear as an 
interaction between group and session, where the administration of levodopa medication between 
sessions would affect individuals with PD in a way not similarly observed in the HOA group. The 
57 
 
researcher predicted that scores for the PD group would increase in the Afternoon session compared to 
the Morning session, while the HOA group would show either no increase or a proportionally smaller 
increase. Instead, both groups did slightly worse in the Afternoon session than the Morning, so there 
was no discernible effect of levodopa administration for this task. The only other experimental task in 
this study to show any effect of Session was Experiment 2a, in which the PD group, but not the HOA 
group, showed slightly diminished performance in the afternoon. Interestingly, these were the two tasks 
for which a ceiling effect was observed, indicating that the observed performance decrements may have 
been the result of boredom or fatigue. 
 The pattern of results for this experiment raises the possibility that lower performance by the 
PD group on this task may not be the result of deficient feature discrimination as such, but instead of 
some yet more fundamental visual process that is adversely affected in PD. However, several factors 
make this unlikely. First, the requirement that all participants in this study, irrespective of group, possess 
either normal or corrected-to-normal vision should minimize the possibility that differences in 
performance were the result of diminished visual acuity in those in the PD group. Further, the use of 
white stimuli against a black background resulted in the maximum possible contrast, meaning that 
group differences cannot be explained by poorer contrast sensitivity in the PD group. Attentional deficits 
are also unlikely to account for the difference, since both groups were given unlimited time to study the 
stimuli and respond. Finally, while there is always a possibility when studying a sample of individuals 
with motor difficulties that mis-keying or other difficulties in responding could account for group 
differences, the non-random nature of the errors in this case makes this unlikely. The interaction 
observed between group and angle in the second analysis indicates that the group difference arises 
disproportionately from trials with smaller angles of rotation where more difficult discriminations were 
required, whereas motor difficulties would likely be more equally distributed across trial types. The 
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researcher therefore posits that differences in performance between the PD and HOA group for this task 
were due to impaired stimulus discrimination per se, and not some other extraneous variable. 
 It is notable that the group difference in Experiment 1 is appreciably smaller than that observed 
in the pilot study, indicating that impairments in basic feature discrimination cannot account entirely for 
the difference observed between groups on the pilot task. However, feature discrimination deficits of 
some in the PD group likely account for some portion of this group difference, and thus will have to be 
taken into account when interpreting Experiments 2 through 4.  
 Aim 2 of the present study was to examine the neural basis of visual impairments observed in 
individuals with PD. As stated at the outset of this experiment, the precise neural correlates of 
performance on this task are difficult to pin down, with a variety of areas implicated across multiple 
studies (Nath & Schwartz, 2016; Vidyasagar & Eysel, 2015; Tranel et al., 2009; Hubel & Wiesel, 1959). 
Previous research indicates that the areas of the healthy brain most likely to be necessary for line 
discrimination are the primary visual cortex (Hubel & Wiesel, 1959) and areas in the right parietal cortex 
(Tranel et al., 2009), and several studies have suggested that individuals with PD may have marked grey 
matter loss in these areas (Melzer et al., 2011; Pereira et al. 2009). Pereira and colleagues go so far as to 
suggest that many of the visuospatial and visuoperceptual difficulties observed in individuals with PD 
are driven by grey matter losses (Pereira et al., 2009). However, the participants in the PD group for 
both Periera et al. (2009) and Melzer et al. (2011) had more severe pathology than those analyzed in the 
present study, and other studies have implicated BG-specific pathology in impairments of line 
orientation judgment (Junqué et al., 1999). We therefore turn to Experiments 2 through 4 to gain a 
better picture of the neural mechanisms involved in impaired perception of visual objects. 
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CHAPTER 6: EXPERIMENTS 2a AND 2b 
6.1 Background 
The presence of DA receptors throughout the cortex (Hurd, Suzuki, & Sedvall, 2001), the 
reciprocal connectivity between the BG and IT (Middleton & Strick, 1996), and the pattern of visual 
deficits observed in previous studies (Weil et al., 2016) raise the possibility that PD may lead to impaired 
processing in IT. Visual processing in IT (and area TE in particular) is generally considered to involve the 
most complex purely visual representations of stimuli in the ventral stream of primates (Tanaka et al., 
1991; Tsunoda et al., 2001; Lehky & Tanaka, 2016). Neurons in this area have been found to selectively 
respond to complex visual features or feature sets of objects. For instance, Logothetis, Pauls, and Poggio 
(1995) measured from 970 IT cells while macaques were presented with a series of complex objects that 
included wire and amoeboid objects. These researchers found that of the 796 neurons that were 
activated by stimulus presentation, some (n = 169) fired preferentially to wire objects while others (n = 
58) responded preferentially to amoeboid objects. Further, subsets of neurons were found that 
responded selectively to a subset of views of a specific object (those nearest to a learned perspective; n 
= 93) and others responded selectively to specific stimuli irrespective of the viewer’s perspective (n = 3). 
In another study, Tsunoda et al. (2001) made electrophysiological recordings of dorsal TE in macaque 
monkeys, including extracellular recordings of individual neurons and intrinsic signal imaging to measure 
activation over a wider cortical region. The latter method revealed “spots” approximately 0.5 x .035 nm 
that selectively responded to objects with common features, such as ellipses or rectangles. These and 
other studies have led researchers to conclude that complex features of objects are represented in 
columns of neurons in IT, and whole objects are represented using a population code that binds these 
columns together (Tsunoda et al., 2001; Lehky & Tanaka, 2016). 
 The foregoing account is consistent with several lesion studies that have examined patients with 
damage to occipitotemporal areas that has largely spared the primary visual cortex. Though lesions that 
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occur outside of a controlled laboratory setting are rarely confined to IT, lesions that include IT have 
been observed to lead to a condition known as apperceptive agnosia, in which individuals show 
impaired recognition for objects but relatively intact basic visual functioning (Warrington & James, 1988; 
Grossman, Galetta, & D’Esposito, 1997) For instance, a study by Grossman, Galetta, and D’Esposito 
(1997) examined two patients with bilateral damage to middle and inferior temporooccipital cortices. 
Both individuals showed significant impairments in object recognition, such as naming common objects 
depicted in line drawings, and match-to-sample tasks that used stimuli such as faces and partially 
overlapping geometric shapes. In both cases, the ability to match simple geometric shapes, as well as 
the ability to draw letters, words, and simple geometric stimuli from memory was relatively (but not 
completely) preserved.  
 There is a body of research indicating that some classes of stimuli are processed differently from 
one another in IT. The most commonly cited example is the processing of faces, in which recognition can 
be disrupted by manipulations (e.g., inversion, presentation in photo negative, etc.) to which the 
recognition of other objects is robust (Farah, Levinson, & Klein, 1995; Farah, et al., 1995; Cooper & 
Wojan, 2000). Indeed, there is an area of the fusiform gyrus in IT known as the fusiform face area, which 
has been posited to be dedicated to the processing of human faces (Kanwisher, McDermott, & Chun, 
1997; McCarthy et al., 1997). Controversy remains about whether this sort of privileged processing is 
restricted to faces, or whether it also extends to other classes of objects for which the user has 
developed expertise (Gauthier et al., 1997), or to any class of stimuli that share a common structural 
description (Lehky & Tanaka, 2016), and a resolution is beyond the scope of the present study. However, 
in testing the effects of PD and levodopa on processing in IT, it was deemed instructive to test 
discriminations both of a class of stimuli discriminable by structural description, and a class of stimuli 
with a uniform structural description. Accordingly, Experiment 2a examines the ability of participants to 
discriminate between stimuli based on the wire objects in Logothetis, Pauls, and Poggio (1995) (i.e., 
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figures composed of a repeated visual primitive randomly arranged), while Experiment 2b examines the 
ability to discriminate between 3D-rendered human faces. 
6.2 Experiment 2a Methods 
6.2.1 Participants 
All participants from the study sample completed this experiment and were included in the 
analysis. See section 3.3 for details concerning sample characteristics and recruitment methods. 
6.2.2 Stimuli 
The stimuli used in this experiment were a new set of tube sculptures generated by the same 
method as those in the pilot study. Each was created as a series of eight points that would fall within the 
surface of a cylinder measuring 20 units high and 10 units in diameter (i.e., all were equidistant from a 
central, vertical axis). These eight points were connected in serial order to form a figure composed of 
seven line segments. The set of points was constrained so that line segments formed by connecting 
them would be limited to between 4 and 10 units in length, and angles formed by adjacent segments 
were constrained to between 90- and 120-degrees.  Once each set of points was calculated and drawn 
using a Python script, they were rejected if the resulting figures contained line segments that 
intersected, or if the figures were not sufficiently tall (i.e., at least 16 units on the vertical axis). Once 
each set of points had been finalized, they were rendered in MatLab2016b 
(https://www.mathworks.com/products/matlab.html). Conversion of these 3D-rendered images into 
.png files suitable for ePrime 2.0 was accomplished using a free open source graphics program called 
Blender (https://www.blender.org/). 
6.2.3 Procedure 
This task was composed of 72 trials. Each trial began with a blank screen that persisted for one 
second, followed by the simultaneous presentation of two tube sculptures slightly offset about the 
horizontal axis. Half of all participants pressed the “z” key if they believed that the two sculptures were 
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the same and pressed the “m” key if they believed the two sculptures were different, while the other 
half of participants received the reverse key mapping. There was no pre-set time limit on each trial, so 
the stimuli remained on the screen until the participants responded. The task was delivered in four 
equal-sized blocks, between which the experiment paused, informed participants of their progress, and 
encourage them to take a break for as long as they liked prior to resuming.   
 
6.3 Results of Experiment 2a 
The effects of PD pathology and levodopa treatment on object discrimination were examined 
using a 2 (Group: PD vs. HOA) x 2 (Session: Morning vs. Afternoon) ANOVA. There was a main effect of 
Group, F(1,26) = 6.37, p = .02, η2p = .197, with the HOA group (M = 99.45%, S.E. = .45%) scoring higher on 
the task than the PD group (M = 97.87%, S.E. = .45%). The interaction between Session and Group was 
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also significant, F(1,26) = 5.65, p = .03, η2p = .178, with the PD group performing better in the Morning 
than the Afternoon, but no corresponding difference in the HOA group. 
 
 The relationship between levodopa administration and task performance for individuals in the 
PD group was also assessed by calculating difference scores for the object discrimination task and the 
motor portion of the UPDRS between sessions and performing a correlational analysis. The correlation 
did not reach significance either when all participants were analyzed (p = .86) or when participants 
whose UPDRS motor scores did not improve for the afternoon session were removed (p = .68). Overall 
performance by the PD group during the Afternoon session was again examined for a relationship with 
PD progression. No relationship was observed between task performance and either UPDRS scores (p = 
.51) or years since disease onset (p = .51). 
6.4 Methods for Experiment 2b 
6.4.1 Participants 
All participants from the study sample completed this experiment and were included in the 
analysis. See section 3.3 for details concerning sample characteristics and recruitment methods. 
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6.4.2 Stimuli 
The stimuli used in this experiment were a new set of face stimuli generated by the same 
method as those in the pilot study. To create each stimulus image, a series of photographs of human 
faces was first collected from Google images. All photographs were required to have closed mouths and 
neutral expressions. Some of the photographs used were of famous individuals, but the subsequent 
rendering process obscured their identities so that they were unrecognizable by the time they were 
presented as stimuli (the researcher dares you to correctly identify one). Half of these photos were of 
men and half were of women. While the rendering process likely obscured any features that would have 
facilitated visual categorization into demographic groups, effort was made to ensure that the initial 
images represented a broad (though incomplete) cross section of individuals. Thus, for each gender 
category, photographs were further selected on the basis of race and region of origin so that the full 
stimulus set contained equal numbers of Asian, Australian Aboriginal, Black, Caucasian, Latina/o, and 
Middle Eastern individuals. Once these photos were collected, a computer program called FaceGen 
(https://facegen.com/) was used to render each face onto a 3-dimensional head. This process removed 
all of the color and hair from the faces so that each could be distinguished only through inspection of its 
structural features. The process also allowed all heads to be rendered at a constant height, so that they 
could not be distinguished on the basis of how closely their edges came to the border of the screen.  
Once these 3-dimensional heads were rendered, they were exported as .obj files and opened in Blender 
(http://www.blender.org), a freeware 3D art program that allowed for precise manipulation of the 
heads in 3-dimensional space. 
6.4.3 Procedure 
This task was composed of 72 trials. Each trial began with a blank screen that persisted for one 
second, followed by the simultaneous presentation of two horizontally aligned face stimuli. Half of all 
participants pressed the “z” key if they believed that the two stimuli were the same and pressed the “m” 
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key if they believed the stimuli were different, while the other half of participants were assigned the 
reverse key mapping. There was no pre-set time limit on each trial, so the stimuli remained on the 
screen until the participants responded. The task was delivered in four equal-sized blocks, between 
which the experiment paused, informed participants of their progress, and encourage them to take a 
break for as long as they liked prior to resuming. 
 
6.5 Results of Experiment 2b 
The effects of PD pathology and levodopa treatment on face discrimination were examined 
using a 2 (Group: PD vs. HOA) x 2 (Session: Morning vs. Afternoon) ANOVA. The results showed a main 
effect of Group, F(1,26) = 10.71, p < .01, η2p = .292, with the HOA group (M = 95.39%, S.E. = 1.51%) 
scoring higher on the task than the PD group (M = 88.39%, S.E. = 1.51%). No other effects or interactions 
were significant. 
The relationship between levodopa administration and task performance for individuals in the 
PD group was also assessed by calculating difference scores for the face discrimination task and the 
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motor portion of the UPDRS between sessions and performing a correlational analysis. The correlation 
did not reach significance either when all participants were analyzed (p = .86) or when participants 
whose UPDRS motor scores did not improve for the afternoon session were removed (p = .65). Overall 
performance by the PD group during the Afternoon session was again examined for a relationship with 
PD progression. No relationship was observed between task performance and either UPDRS scores (p = 
.51) or years since disease onset (p = .94). 
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6.6 Discussion of Experiments 2a and 2b 
 The results of both Experiment 2 tasks support the hypothesis that individuals with PD are 
impaired at making discriminations of complex visual objects compared to their healthy counterparts. 
While an initial examination of the mean differences between groups for both tasks (1.59% for object  
discrimination, 7.00% for face discrimination) seems to indicate that the PD group was 
disproportionately impaired for faces relative to objects, a ceiling effect on the object discrimination 
task may be acting to mask larger differences in overall object discrimination ability. The finding that 
either group showed any difference in performance between the two stimulus types was unexpected, 
given that no similar difference was observed in the pilot task. One possible explanation for this 
difference may be that the two types of stimuli used in this task were differentially susceptible to 
proactive interference, and that the interleaving of stimulus types in the pilot study facilitated a release 
from this proactive interference while the block design of Experiments 2a and 2b did not (However, see 
Experiment 3). 
 Aim 1 of the current study was to examine any effect of DA and dopaminergic medications on 
visual processing. While the face discrimination task provided no evidence of any effect of medication, 
the Group x Session interaction in the object discrimination task raised the possibility that the 
administration of levodopa had caused the PD group to perform worse in the afternoon that the 
morning. This is, in fact, the pattern of results predicted by Model 3 outlined above, in which levodopa 
causes an excess of DA that in turn causes dysfunction in the preserved DA circuitry of PD patients (see 
Section 1.6.3). However, the fact that no similar effect was observed in face discrimination makes this 
explanation somewhat problematic. Embracing the Dopamine Overdose Hypothesis in this instance 
would require either the assumption that excess DA was having differential effects on overlapping 
neural circuitry that was required for both tasks, which seems unlikely, or that excess DA 
disproportionately affected circuitry that was uniquely recruited for the face discrimination task. While 
68 
 
research indicating that face perception relies on specialized neural mechanisms (e.g., Kanwisher, 
McDermott, & Chun, 1997) seems compatible with the latter assumption, it is not obvious why there 
should be such differences in dopaminergic circuitry within a relatively small region of the temporal 
cortex. Failure to find any effect of session in Experiment 3 also casts doubt on a Dopamine Overdose 
explanation. In contrast, the fact that the PD group performed worse later in the day on a task for which 
they performed at or near ceiling in the morning adds to evidence from Experiment 1 that boredom or 
fatigue may have played a role in performance decrements in the Afternoon session. Indeed, one likely 
possibility is that what appears to be an interaction between group and session in the object 
discrimination results is actually separate effects of group and session, analogous to those observed in 
Experiment 1, but in this case the group effect for the morning session is masked by a ceiling effect. 
 The results of Experiments 2a and 2b are largely consistent with previous studies showing that 
individuals with PD tend to perform worse than their healthy counterparts at visual discrimination of 
complex visual stimuli. With respect to non-face objects, Laatu et al. (2004) showed that participants 
with PD were impaired relative to control participants at discriminating between line drawings of 
common objects and “scrambled” versions of those same objects in which features had been re-
arranged. This finding in particular is suggestive of involvement by IT, since it is similar to some forms of 
apperceptive agnosia (see Section 6.1). With respect to faces, Levin et al. (1991) have previously showed 
that individuals with PD tend to perform worse than their healthy counterparts at the Benton Facial 
Recognition Test (BFRT), though there are several notable differences between the current task and the 
BFRT. In the BFRT, participants are simultaneously presented with a target photograph of one individual 
and an array of six test photographs: three that depict the same individual at angles other than the one 
used in the target photograph, and three that depict a different individual of similar appearance from 
various angles. Participants in this task are instructed to select the three test photographs that depict 
the individual in the target photo (Ducheine & Weidenfeld, 2003). The BFRT thus adds the requirement 
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that participants make discrimination judgements based on unseen perspectives of the person depicted, 
which may affect the cognitive demands of the task in unforeseeable ways. It is also notable that 
individuals completing the BFRT must make three correct judgments for each trial to be scored as 
correct, while Experiment 2b of the current study only requires one such judgment.  
In contrast to the present study, Jacobs et al. (1995) found no difference between individuals 
with PD and healthy control participants in performance on the Facial Identity Discrimination task of the 
Florida Affect Battery-revised. The Facial Identity Task in the Florida Affect Battery-revised instructs 
participants to make a same/different judgment of two simultaneously presented photographs of faces, 
making it more procedurally similar to the current study. One possible explanation for the discrepancy in 
results is the incomplete masking of non-face cue in the Florida Affect Battery-revised, which is 
accomplished by using surgical caps to cover the hair of the individuals depicted. This procedure 
preserves the eyebrows and hairline of the subjects depicted in the task images, characteristics that 
have been shown to be sufficient for discrimination of face stimuli even when facial features are 
obscured (Ducheine & Weidenfeld, 2004). It is therefore possible that individuals with PD in Jacobs et al. 
(1995) were able to rely on non-face cues and bypass impaired face processing circuitry. By using 3-
dimensional face stimuli that had been filtered to remove all non-face cues to identity, the task used in 
the present study required participants to make discrimination judgments solely on the basis of the 
structural features of face stimuli. 
 The mean difference between the two groups for these two tasks (1.58% for objects, 7.00% for 
faces) are still appreciably below the group difference observed in the pilot task (18.28%). It is therefore 
likely that differences observed between the PD group and the HOA group in the pilot study were driven 
by more than object and face discrimination deficits in members of the PD group. However, such deficits 
likely account for an appreciable portion of group difference in performance on the pilot task, and will 
have to be taken into account when interpreting Experiments 3 and 4.  
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Given the ceiling effects observed in both Experiment 1 and Experiment 2a, comparisons 
involving effect size for either task (let alone both) are likely to be misleading. However, it bears 
mentioning that while the mean difference between groups for Experiment 2b was greater than that of 
Experiment 1 (4.44%), the mean difference for Experiment 2a was not, so it is difficult to put much stock 
in this comparison. Consequently, while the group difference for the face discrimination task cannot be 
completely accounted for by the more basic feature discrimination deficits observed in Experiment 1, 
the same cannot be said conclusively of the object discrimination task. In other words, it is possible that 
the deficit in feature processing observed in the PD group for the line discrimination task may be 
sufficient to explain the lower performance by the PD group on the object discrimination task. The 
finding by Laatu et al. (2004) that individuals with PD performed worse than healthy individuals when 
discriminating drawings of familiar objects from scrambled versions of those drawings raises the 
possibility that individuals with PD may show impairment for the binding of features and not just the 
perception of these features themselves. It would be useful to know if errors made by participants with 
PD in this study were random or systematic. For instance, if participants were biased toward saying that 
drawings of objects were the same independent of the arrangement of their features, this could be 
taken as evidence that features were being accurately perceived, but the relationships among them 
were not, and that PD was thus disrupting processing at the whole-object level. However, this 
information was not reported by the authors. 
 Aim 2 of the present study was to examine the neural basis of visual impairments observed in 
individuals with PD. A major motivation behind Experiment 2 was to include tasks in this study that were 
known to recruit processing from IT in general and the fusiform gyrus in particular to see if these 
requirements led to a disproportionate drop in task performance by the PD group. This would have the 
effect of implicating IT as a weak link in ventral visual pathway-dependent processing. In addition to V1 
and other early visual areas thought to be necessary for the performance of the line discrimination task 
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in Experiment 1, areas of IT have been shown to be necessary for the discrimination of complex objects 
and faces, such as those in Experiment 2 (Lehky & Tanaka, 2016). While the results of Experiment 2a fail 
to conclusively demonstrate the existence of object discrimination deficits beyond those resulting from 
more basic deficits of feature discrimination, to the extent that any individuals in the PD group showed 
disproportionately greater impairment in Experiment 2, it is reasonable to suspect that impaired IT 
processing could be responsible. This hypothesis is supported by a study of individuals with PD that 
correlated impaired performance on object perception tasks with grey matter loss in the cortex. Pereira 
et al. (2009) asked participants with PD and healthy control participants to complete the Benton visual 
form discrimination test (VFDT) as well as the BFRT, and grey matter volume was analyzed for each 
individual using MRI. The results of this study showed that, relative to their healthy counterparts, 
individuals with PD showed decreased grey matter density in regions of the frontal, parietal, and 
temporal lobes, as well as in several subcortical regions. Importantly for the current study, deficits in the 
BFRT task were associated with grey matter loss in the ventral occipitotemporal cortex, and the fusiform 
gyrus in particular. In contrast, performance deficits on the VFDT were associated with grey matter loss 
in visual association areas in bilateral superior parietal cortex. The fact that VFDT performance was not 
associated with IT processing may be related to the nature of the stimuli used in this task. The VFDT is a 
match-to-sample task in which the target stimulus consists of three simple geometric shapes, and 
distractors are generated by either moving, rotating, or distorting one of the three shapes (Campo & 
Morales, 2003). Discrimination in this task may thus depend on the spatial transformation of task 
stimuli, and the parietal areas identified by Periera et al. (2009) have indeed been associated with 
performance on location and spatial discrimination tasks (Haxby et al., 1991).  
While Experiment 2a was intended as a test of the ability to visually discriminate complex 
objects, there was nothing in the design of this task that would have prevented participants from 
making their judgments by focusing on subsets of features in each figure without processing the figures 
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as a whole. Indeed, it would have been possible for participants to base their judgments on single 
segments of each figure, making the stimuli in this task, in effect, noisier versions of the line stimuli in 
Experiment 1. This is largely a result of the way the study was developed, since the tube sculpture 
figures were used in the pilot study before it became apparent that a control task, such as line 
discrimination, would be prudent. However, it was also not obvious a priori whether or not participants 
would choose to adopt a feature-based task strategy for the object discrimination task. Further, it was 
not clear that participants would even be able to employ such a strategy if PD or levodopa produced a 
perceptual deficit for complex objects, since the ability to identify corresponding segments between 
different stimulus figures for comparison necessitates some minimal understanding of the relationship 
between individual segments and the larger figures. For example, it would be difficult to “cheat” on this 
task by only comparing only the “end” tubes of each figure if one could not perceive the sculptures as 
having discernible ends in the first place. So, despite some perceptual overlap with the stimuli in 
Experiment 1, the object discrimination task had the potential to provide instructive observations: Any 
pattern of results would indicate whether or not individuals could successfully differentiate the different 
stimuli in each experiment, but in the case where an individual did well on both tasks, it could not be 
ruled out that successful performance on complex object discrimination was the result of a feature-
based discrimination strategy. In any case, the difficulty in comparing results across Experiments 1 and 
2a that arose from the ceiling effects on both means that questions of strategy cannot be resolved on 
the basis of the data collected. 
In summary, the results of Experiment 2 support the existence of face discrimination deficits in 
individuals with PD, and previous studies have suggested grey matter atrophy in ventral visual pathway 
structures as a possible cause. Failure to find any effect of DA manipulation in Experiment 2 is consistent 
with the proposed mechanisms. However, further research is required to establish the existence of, and 
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any neural underpinnings for, deficits in non-face object discrimination beyond those of simple feature 
discrimination in individuals with PD. 
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CHAPTER 7: EXPERIMENT 3 
7.1 Background 
 Experiments 3 and 4 address the functionality of pathways projecting from IT to other areas of 
the brain involved in complex visual tasks. Specifically, Experiment 3 examines changes in the ability of 
individuals with PD to maintain visual representations over a brief delay, which is thought to involve a 
complex interplay between IT and the PFC. 
 The roles that these two areas play in VWM is still a matter of considerable debate. The sensory 
recruitment model posits that the contents of working memory are a result of reactivation of the 
sensory cortices involved in the encoding of the relevant representations, and the role of the PFC is 
largely to supervise the process of reactivation (Gayet, Paffen, & Van der Stigchel, 2018; Scimeca, 
Kiyonaga, & D’Esposito, 2018). An opposing view, advanced by Xu (2017), is that the representations 
that form the contents of working memory are principally stored in PFC, with visual sensory cortices 
being nonessential (Xu, 2017). Other accounts are notably more nuanced. For instance, Courtney et al. 
(1997) conducted an fMRI study of human participants performing a working memory task using faces 
as stimuli and found multiple areas in both ventral occipitotemporal cortex and PFC where activity was 
modulated by the task. Of the three areas identified in the visual cortex, the two located more anteriorly 
showed activity that was not only sustained over a delay, but which was also preferentially activated by 
face stimuli as opposed to control stimuli. The three areas identified in PFC displayed a spectrum of 
response properties, with posterior middle frontal cortex producing disproportionately transient 
activation in response to visual stimuli in the task with minimal sustained activation, the anterior middle 
frontal cortex showing the opposite pattern, and the inferior frontal cortex displaying intermediate 
levels of both transient and sustained activations. This pattern is interpreted by the authors as indicating 
that both ventral occipitotemporal cortex and PFC contain hierarchies of processing including both 
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sensory processing and working memory maintenance. In other words, visual working memory is the 
result of both cortical areas working in concert at a variety of processing levels. 
 Additionally, studies of VWM in monkeys have identified cells that exhibit sustained activation 
during delay intervals that is selective for object identity. Rao, Rainer, and Miller (1997) recorded from 
neurons in the lateral PFC of monkeys and found cells that responded selectively to a remembered 
object during a memory delay, as well as cells whose activity was driven by both object identity and 
object location. These findings were replicated by Rainer, Asaad, and Miller (1998), and Courtney et al. 
(1996) have used positron emission tomography with human participants and identified areas in lateral 
PFC that were selectively activated by faces in a VWM task, independent of their location. While these 
studies cannot speak to the richness of visual representations in the PFC, and there has been no 
suggestion to date that such representations are retinotopically organized as they are in IT or other 
areas of the ventral visual pathway, it does seem plausible that information pertaining to object identity 
is represented in PFC above and beyond what is needed to reactivate the relevant areas of visual cortex. 
Further, while both PFC and IT in monkeys have been shown to maintain stimulus-selective information 
over delays, only in PFC is this activity maintained following the presentation of new visual stimuli to 
which the animals are required to attend (Miller, Erickson, & Desimone, 1996). 
7.2 Methods 
7.2.1 Participants 
All participants from the study sample completed this experiment and were included in the 
analysis. See section 3.3 for details concerning sample characteristics and recruitment methods. 
7.2.2 Stimuli 
The face and object stimuli used in this task were generated by the same methods used in 
Experiments 2a and 2b, as well as the Pilot study. However, a new set of these stimuli were created for 
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this experiment, such that no face or tube sculpture was reused across tasks or sessions. See sections 
6.2.2 and 6.4.2 for a complete description of these stimuli. 
7.2.3 Procedure 
 
This task was composed of 72 trials. Each trial in this task comprised a Study period and a Test 
period. During the Study period (2500 ms), participants were asked to study and remember an object or 
face presented on the screen. The Study period was followed by one of the three designated delay 
intervals.  While the delay in the Pilot study was a constant 3000 ms, in Experiment 3 only one-third of 
the trials had a 3000 ms delay, while another one-third had a 1000 ms delay, and another third had a 
5000 ms delay. The delay was followed by a Test period in which participants were asked to indicate 
whether an object or face that subsequently appeared on the screen was the same as or different than 
the object presented in the Study period. In contrast to the pilot study, in Experiment 3, stimuli that 
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were the same were always presented at the same angle during Study and Test periods. Half of all 
participants were instructed to respond by pressing “z” if they believed the object or face was the same 
and “m” if the object or face was different, while the other half of participants were assigned the 
reverse key mapping. There was no pre-set time limit on each trial, so the stimuli remained on the 
screen until the participants responded. The task was delivered in four equal-sized blocks, between 
which the experiment paused, informed participants of their progress, and encouraged them to take a 
break for as long as they liked prior to resuming. 
7.3 Results 
 
The effect of PD pathology and levodopa treatment on VWM were examined using a 2 (Group: 
PD vs. HOA) x 2 (Session: Morning vs. Afternoon) x 2 (Stimulus Type: Objects vs. Faces) x 3 (Delay: 1000, 
3000, and 5000ms) mixed factorial ANOVA. The results showed a main effect of Group, F(1,26) = 4.62, p 
= .04, η2p = .151, with the HOA group (M = 80.75%, S.E. = 1.50%) scoring higher than the PD group (M = 
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76.19%, S.E. = 1.50%). There was also a main effect of Stimulus Type, F(1,26) = 224.20, p < .001, η2p = 
.896, with participants across groups performing better on Object trials (M = 91.17%, S.E. = 1.47%) than 
Face trials (M = 65.77%, S.E. = 1.24%), as well as a main effect of Delay, F(2,52) = 6.98, p < .01, η2p = .212, 
with participants across groups performing better on both the 1000ms delay trials (M = 80.21%, S.E. = 
1.57%) and 3000ms delay trials (M = 81.10%, S.E. = 1.30%) than on the 5000ms delay trials (M = 74.11%, 
S.E. = 1.84%). No other effects or interactions were significant. 
 
The relationship between levodopa administration and task performance for individuals in the 
PD group was also assessed by calculating difference scores for the VWM task and the motor portion of 
the UPDRS between sessions and performing a correlational analysis. The correlation did not reach 
significance either when all participants were analyzed (p = .71) or when participants whose UPDRS 
motor scores did not improve for the afternoon session were removed (p = .43). Overall performance by 
the PD group during the Afternoon session was again examined for a relationship with PD progression. 
79 
 
No relationship was observed between task performance and either UPDRS scores (p = .45) or years 
since disease onset (p = .90). 
7.4 Discussion 
 Experiment 3 was designed largely as a replication of the pilot study, absent the now defunct 
stimulus rotation manipulation. Accordingly, the results again demonstrated that individuals with PD 
tend to be worse than their healthy counterparts at tasks that require maintaining visual 
representations over a delay. While the group effect itself remained, it is notable that the difference in 
group means in Experiment 3 (4.56%) was appreciably smaller than that of the pilot study (18.28%). 
Given the difference between the two studies, several factors may account for this rather large 
discrepancy. First, the narrowed age range for the main study resulted in the exclusion of primarily older 
individuals. This may have not only reduced the variability in task performance due to age-related 
cognitive decline, but also excluded participants from the PD group with longer disease durations and 
thus greater disease-related deficits. Consistent with this latter point, it can be seen that the scores for 
the PD groups rose appreciably in the main study (66.41% in the pilot study vs. 76.19% in Experiment 3) 
while the HOA groups were closer between studies (84.69% in the pilot study vs. 80.75% in Experiment 
3). Second, the larger sample in the main study meant that there was less of an opportunity for more 
extreme scores to overly influence the group average. Additionally, it is possible that the refinements 
implemented in the study design (displaying the key mappings on the screen, adding an acclimation 
task, adding breaks to the task procedures) disproportionately advantaged individuals in the PD group. 
Within-task breaks were likely particularly helpful given that increased fatigue is a common symptom of 
Parkinson’s disease, with clinically significant fatigue observed in 33-58% of disease sufferers, depending 
on the study (Friedman et al., 2006). Thus, the effect of group in the present experiment likely 
represents a more valid measurement of the effects of PD on VWM task performance. 
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 The effect of stimulus type was larger in Experiment 3 than either Experiment 2 or the pilot 
study. While the effect in Experiment 2 may have been reduced by a ceiling effect for the object 
recognition task, the same cannot be said for the pilot task. In the discussion for Experiment 2, the 
researcher speculated that the reason for the discrepancy might have been due to a buildup of 
proactive interference for faces in Experiment 2, since the pilot study prevented such an issue by 
interleaving face and object trials. However, in Experiment 3, the order of the two stimulus trial types 
was randomized. Accordingly, if proactive interference had been the whole story behind the effect of 
stimulus type, then the size of the effect for Experiment 3 should have been somewhere in between 
that in Experiment 2 and the pilot study, which was not the case. It cannot be that the delay in 
Experiment 3 somehow exacerbated the effect of stimulus type in Experiment 2, because a retention 
interval was also present in the pilot study, which showed no effect of stimulus type. So while the results 
of Experiments 2 and 3 provide strong evidence that individuals in both groups were more proficient at 
discriminating the abstract object stimuli than the face stimuli used in this study, it is unclear what 
factors are driving the magnitude of this difference across tasks.  
 Aim 1 of the current study was to examine any effect of DA and dopaminergic medications on 
visual processing. No effect of session was observed for this experiment, either as a main effect or an 
interaction. This observation supports the conclusion that levodopa administration has no appreciable 
effect on performance of VWM tasks by individuals with PD. 
 The mean difference between the two groups in Experiment 3 (4.46%) fell between the mean 
differences for the object discrimination (1.58%) and face discrimination (7.00%) tasks in Experiment 2. 
This observation is consistent with the idea that the group effect for the VWM task could be explained in 
large part by the comparatively lower performance of the PD group in discriminating the stimuli 
themselves, absent any effect of difference in working memory ability. The main effect of delay 
observed in Experiment 3 indicates that the manipulation of retention interval used was sufficient to 
81 
 
modulate the accuracy of participants’ judgments. However, no interaction was observed between 
group and delay that might have indicated that the PD group was disproportionately affected by the 
working memory aspect of this task. As a result, it is unclear from the present study to what extent the 
main effect of group can be explained by deficits in VWM.  
Aim 2 of the present study was to examine the neural basis of visual impairments observed in 
individuals with PD. A major motivation behind Experiment 3 was to include a task in this study that was 
known to recruit processing from the PFC to see if this requirement led to a disproportionate drop in 
task performance by the PD group. This would have the effect of implicating the PFC as a weak link in 
ventral visual pathway-dependent processing. However, the results of the current study are not 
sufficient to tease apart to relative contribution of PFC -dependent VWM and ventral pathway-
dependent perceptual discrimination impairments to diminished performance on this task. Other 
research suggests that the PFC is necessary for the maintenance of visual representations of unseen 
stimuli in both monkeys (Miller, Erickson, & Desimone, 1996) and humans (Haxby et al., 2000; Courtney 
et al., 1997), and that PD is associated with pathology of the frontal lobe (Double et al., 1996). Likewise, 
behavioral research has indicated that individuals with PD show impairment on PFC-dependent tasks, 
even relatively early in the course of the disease (Muslimović et al., 2005; Cools et al., 2003). Further 
research should be conducted to investigate whether impairments to VWM observed in individuals with 
PD, such as the one reported here, are associated with neurological degeneration of the PFC.  
Experiment 4 will again examine deficits in PD for tasks associated with frontal lobe function, 
but within the context of mental transformation of visual representations rather than their 
maintenance.   
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CHAPTER 8: EXPERIMENT 4 
8.1 Background 
Mental rotation can be conceptualized as an extension of VWM in that it requires the 
maintenance of visual representations in the brain, but with the additional requirement of manipulating 
those representations in a goal-directed fashion. Predictably then, mental rotation has been shown to 
employ the ventral visual pathway, which is involved in processing of objects, and frontal areas involved 
in the maintenance of working memory, as discussed above. However, this task also involves the 
interface between the ventral and dorsal visual pathways and, of particular interest in a study examining 
PD pathology, several motor areas of the brain. With respect to the visual areas discussed previously in 
this study, imaging studies have shown the primary visual cortex to be active during mental rotation 
tasks (Jordan et al., 2001), as well as bilateral extrastriate areas (Tagaris et al., 1997, Zacks 2008) and IT 
in particular (Jordan et al., 2001). Additionally, imaging studies show areas in the frontal lobe to be 
active during mental rotation tasks. This includes regions of the right superior, middle, and inferior 
frontal gyri (Jordan et al., 2001; Tagaris et al., 1997), as well as bilateral PFC (Zacks, 2008; Cohen et al., 
1996). 
 Briefly, the dorsal visual pathway emerges from the primary visual cortex of the brain and 
travels anteriorly via a more dorsal route, as its name would suggest. This pathway is disproportionately 
involved in spatial processing, and the constituent region with the highest level of processing is 
commonly considered to be the posterior parietal cortex (PPC), which surrounds the intraparietal sulcus 
(Janssen, Verhoef, & Premereur, 2018). The PPC is functionally divided into cortical areas that appear to 
be organized around “effectors”, such that the medial intraparietal and anterior intraparietal areas 
whose activity is associated with reaching and grasping movements (respectively), and lateral 
intraparietal area whose activity is associated with visual saccades. Notably, activity in the caudal 
intraparietal area has been implicated in tasks requiring three-dimensional visual processing (Katsuyama 
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et al., 2010). Imaging studies of participants completing mental rotation tasks have identified task-
related activations in bilateral PPC (Christophel et al., 2015; Cohen et al., 1996), particularly in the areas 
of the intraparietal sulcus (Zacks, 2008; Jordan et al., 2001) and the superior parietal lobule (Tagaris et 
al., 1997). 
 That the mental manipulation of objects in space involves areas with known roles in object and 
spatial processing, as well as working memory and executive functions, is perhaps not terribly surprising, 
and pathways have been identified between these areas that could support a functional interface 
(Janssen et al., 2018, Amick et al., 2006; Middleton & Strick, 2000). Less clear is the role of motor regions 
in mental rotation, where task-relevant activity has also been identified (Zacks, 2008; Jordan et al., 2001; 
Tagaris et al., 1997). Several transcranial magnetic stimulation (TMS) studies have been conducted 
examining this question, but the results have not lent themselves to straightforward interpretation. For 
instance, a study by Cona, Marino, and Semenza (2017b) applied short trains of pulses over the 
supplementary motor area (SMA) and primary motor cortex (M1) at 350 ms following the visual 
presentation of pairs of abstract objects and hands. The SMA has been implicated in the planning of and 
preparation for complex movements (Ohara et al., 2000), while M1 has been implicated in the execution 
of movements and movement sequences (Karni et al., 1998), In the study, participants were asked to 
judge whether the stimulus pairs were the same or mirror images of one another, and the stimuli could 
be rotated in depth with respect to one another at either 0, 50, 100, or 150 degrees. The researchers 
reported that tetanic stimulation over the SMA reduced the number of errors that participants made on 
the task at higher angles of rotation (i.e., 100 and 150 degrees), but only when the stimuli compared 
were abstract objects and not hands. However, while the same train of TMS stimulation over M1 
produced no significant changes in rotation performance in that study, a different study by Ganis et al. 
(2000) found that a single pulse of TMS administered to M1 at 650 ms post-stimulus increased error 
rates for individuals performing mental rotation of hand and foot stimuli, but only for one of the four 
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rotation angles used (60 degrees out of 20, 60, 100, and 140 degrees). Another study by Cona, Marino, 
and Semenza (2017a) used TMS over the dorsal premotor cortex (PMd) of individuals performing mental 
rotations on pairs of objects and hands and found that TMS impaired accuracy in the mental rotation of 
objects, but only on trials where the correct response was “same”. Activations of the PMd have been 
associated with the planning and visual guidance of movements (Cisek & Kalaska, 2005). 
 Some researchers have suggested that any visual object that the brain registers as graspable 
automatically primes mental representations of motor actions related to that object (Grèzes & Decety, 
2001). On this account, activity observed in motor areas during mental rotation is an epiphenomenon 
and should show no strong association with task performance. Other researchers have argued that SMA 
and PMd, though commonly identified principally as motor regions, actually subserve domain-general 
processing. For instance, Cona and Semenza (2017) posit that the SMA is involved in sequence 
processing for a broad array of cognitive tasks involving timing, numerical cognition, working memory, 
language, music perception/production, and spatial processing. In support, the authors cite studies 
showing that SMA activity increases with the duration of synchronization-continuation tapping tasks 
(Crowe et al., 2014), the amount of angular rotation in mental rotation tasks (Milivojevic, Hamm, & 
Corballis, 2009), the number of operands in an arithmetic problem (Menon et al., 2000), and the 
complexity of improvisations produced by musicians (Bengtsson, Csikszentmihalyi, & Ullén, 2007). They 
also note that damage to the SMA has been shown to cause dysfluent speech (Ziegler, Killan, & Dieger, 
1997), deficits in producing sequential memory-guided saccades (Gaymard, Pierrot-Deseilligny, & 
Rivand, 1990), and varying degrees of akinesia (Potgieser et al., 2014). While a subset of the examples 
cited by Cona and Semenza (2017) seem as though they could be equally well explained by a more 
general role for SMA in working memory, the authors also refer to several single-unit recording studies 
of the SMA in monkeys that identified cells with sequence-specific response properties, such as coding 
the specific order of a task in a larger sequence (e.g., a cell active up to the third movement in a series), 
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and cells that responded specifically to either even- or odd-numbered events in a series (Shima & Tanji, 
2000).  
In a similar vein, Ptak, Schnider, and Fellrath (2017) have proposed that the PMd and the 
superior parietal cortex form a network that facilitates emulations of actions and movements, 
irrespective of the effector. The authors refer to this network as the dorsal frontoparietal network 
(dFPN) and characterize its activity as creating a dynamic representation of objects and movements in 
space for the purposes of manipulation, prediction, and online error. As evidence, they point to research 
indicating a high degree of overlap in activations across dFPN between imagined and executed actions, 
as well as studies showing motor compatibility effects such as interference between imagined 
movements and actual movements that are incompatible in real space (ctd. in Ptak, Schnider & Fellrath, 
2017). Both of these latter models offer plausible – and not mutually exclusive – explanations for the 
recruitment of nominally motor areas during mental rotation tasks that require the manipulation of 
mental representations into orientations not available through direct perception. Neither the sequence 
processing nor the dFPN model posits an explanation for research showing M1 recruitment in mental 
rotation tasks.  
The current experiment is not designed to adjudicate on these competing explanations, since 
they only predict that motor areas will be recruited during mental rotation. However, this processing 
demand, if it exists, is unique among experiments in the current study, such that a disproportionately 
large performance deficit by the PD group on this task would provide evidence that the motor areas 
themselves, and not upstream visual processing, are responsible for mental rotation impairments 
observed in PD. 
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8.2 Methods 
8.2.1 Participants 
Following completion of this task, one participant in the PD group asked several questions that 
gave a strong impression that this individual had not completely understood or followed the instructions 
for this experiment. When asked more directly if this individual felt they had performed the task 
correctly the individual replied that they had. However, given the uncertainty on the part of the 
experimenter, and out of an abundance of caution, this participant’s data, as well was that of their 
matched control, were omitted from further analysis for this task. All other participants from the study 
sample completed this experiment and were included in the analysis. See section 3.3 for details 
concerning sample characteristics and recruitment methods. 
8.2.2 Stimuli 
 Because the rotation manipulation in the pilot study was unsuccessful in producing an 
observable disruption in stimulus processing, this experiment was designed to more closely resemble a 
study by Lee et al. (1998) in which an effect of angular rotation on task performance was observed. To 
this end, the stimuli used were a set of perspective line drawings of novel 3-dimensional objects. This 
stimulus set was developed by Ganis and Kievit (2015) as an update to a classic stimulus set developed 
by Shepard and Metzler (1971). The objects consisted of 7-11 cubes serially connected face-to-face in 
such a way that four 90-degree angles were formed along the length of the object. On each trial, two of 
the line objects were simultaneously presented on the screen, aligned horizontally. On half of all trials, 
both stimuli had the same structural description, while on the other half one of the four angles were 
changed in orientation to slightly alter the figure. Further, stimuli were rotated with respect to one 
another by either 0, 50, 100, or 150 degrees about the Y-axis. 
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8.2.3 Procedure 
This task was composed of 36 trials. Each trial began with a blank screen that persisted for one 
second, followed by the simultaneous presentation of two horizontally aligned object stimuli. Half of all 
participants were instructed to press the “z” key if they believed that the two stimuli were the same and 
the “m” key if they believed the stimuli were different, while the other half were instructed to use the 
reverse key mapping. There was no pre-set time limit on each trial, so the stimuli remained on the 
screen until the participants responded. The task was delivered in four equal-sized blocks, between 
which the experiment paused, informed participants of their progress, and encouraged them to take a 
break for as long as they liked prior to resuming.   
 
8.3 Results 
This experimental task is in large part a replication of Lee et al. (1998). Among other findings, 
these authors reported that some of the effects in their analyses were mediated by whether the 
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abstract objects were the same or different during stimulus presentation. As such, the present analysis 
examined the role of Same vs. Different on participants’ task scores. The effects of PD pathology and 
levodopa treatment on mental rotation were thus examined using a 2 (Group: PD vs. HOA) x 2 (Session: 
Morning vs. Afternoon) x 2 (Identity: Same vs. Different) x 4 (Angle: 0, 50, 100, and 150) mixed factorial 
ANOVA. There was a main effect of Group, F(1,24) = 12.043, p < .01, η2p = .334, with the HOA group 
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making more correct judgments (M = 93.63%, S.E. = 2.31%) than the PD group (M = 82.32%, S.E. = 
2.31%). There was also a main effect of rotation angle, F(3,72) = 3.25, p = .03, η2p = .119, with both 
groups performing better on trials with 0° of rotation (M = 91.99%, S.E. = 1.96%) than trials with 50° (M 
= 88.36%, S.E. = 2.38%), 100° (M = 85.68%, S.E. = 2.00%), or 150° (M = 85.90%, S.E. = 2.26%) of angular 
rotation. No other effects or interactions rose to the level of significance.  
The relationship between levodopa administration and task performance for individuals in the 
PD group was also assessed by calculating difference scores for the mental rotation task and the motor 
portion of the UPDRS between sessions and performing a correlational analysis. The correlation did not 
reach significance either when all participants were analyzed (p = .63) or when participants whose 
UPDRS motor scores did not improve for the afternoon session were removed (p = .32). Overall 
performance by the PD group during the Afternoon session was again examined for a relationship with 
PD progression. No relationship was observed between task performance and either UPDRS scores (p = 
.17) or years since disease onset (p = .22). 
8.4 Discussion 
 The results of Experiment 4 are consistent with the finding by Lee et al. (1998) that individuals 
with PD are impaired at mental rotation relative to their healthy counterparts. Indeed, the mean 
difference observed between the two groups in this study (11.31%) was the largest observed in any of 
the five experiments in this study. This observation is particularly striking given that this was not the 
most difficult of the five experimental tasks, as judged by the performance of the HOA group, which 
served as a baseline for this study. This finding raises the possibility that the impairment observed for 
the PD group in this task may be of a qualitatively different nature than those observed for the first four 
tasks, and that one or more of the unique processing requirements of this task disproportionately 
disadvantaged the PD group.  
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 The main effect of angle observed in the present study indicates that the rotation manipulation 
was sufficient to disrupt discrimination judgments for the object rotation task. However, both groups 
appear to have been similarly affected, as there was no interaction between angle and group. This lack 
of interaction is at odds with the findings of Lee and colleagues. In their study, Lee et al. (1998) found 
that their PD group was disproportionately impaired at the highest angles of stimulus rotation when the 
two stimuli were the same. In particular, when stimuli were rotated more than 120° in depth, the PD 
group in that study actually performed worse than chance, indicating that they had adopted a 
maladaptive strategy for making their discrimination judgments. In contrast, individuals with PD in the 
present study were still averaging 80.77% correct for the same trial type.  
Several factors may account for this difference in results. The sample size for the current study 
was almost twice the size used by Lee and colleagues, making it less likely that results would be unduly 
influenced by one or two individuals using a counterproductive task strategy. Perhaps more significantly, 
the stimulus set used in the present study differed from that used by Lee et al. in the way that 
“different” stimuli were generated. Specifically, Lee et al. used the traditional Shepard and Metzler 
(1971)-type stimuli where objects in the “different” condition were all mirror images of one another. In 
contrast, the present study used stimulus set developed by Ganis and Kievit (2015) where objects in the 
“different” condition were “pseudo-mirror” images of one another, and therefore not always chiral 
(Ganis & Kievit, 2015, pg. 2). The inclusion of these non-chiral stimuli may have been sufficient to disrupt 
the adoption of whatever maladaptive strategy produced the interaction in Lee et al. (1998).  
 Aim 1 of the current study was to examine any effect of DA and dopaminergic medications on 
visual processing. No effect of session was observed for this experiment, either as a main effect or an 
interaction. This observation supports the conclusion that the manipulation of DA levels in the brain has 
no appreciable effect on performance of mental rotation tasks by individuals with PD. 
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 It is worth noting that not all mental transformations of objects have been observed to be 
disrupted in PD, and the 3D manipulation of objects used in this study may be an exception rather than 
the rule. For instance, the pilot task in this study required participants to mentally transform 3D stimuli 
by rotating them to unseen perspectives, but this manipulation produced no appreciable group 
difference in accuracy. In that task, the smaller angles of rotation resulted in a comparatively smaller 
disruption in the spatial relationships among features, so this difference in results may simply have been 
one of degree. However, Lee et al. (1998) also included a task that required participants with and 
without PD to make discriminations of Shepard and Metzler stimuli that were rotated within the picture 
plane, instead of in depth. Stimuli in this task were rotated by the same angles as used in the depth 
rotation task, but the researchers observed no difference in accuracy between groups. Similarly, Ogden, 
Growdon, and Corkin (1990) administered the Spatial Relations task of the Differential Aptitude Test to 
individuals with PD and healthy control participants, a task that requires participants to match a target 
stimulus with a picture of what that stimulus would look like if folded along an indicated axis. These 
researchers similarly observed no difference in accuracy between groups. It may therefore be some 
processing demand unique to mental rotation at large angles in depth that is impaired in individuals 
with PD, rather than a more general deficit in the mental transformation of objects. 
 Aim 2 of the present study was to examine the neural basis of visual impairments observed in 
individuals with PD. Of all the tasks administered in the present study, the results of the mental rotation 
task in Experiment 4 seem to represent the best case for a group difference that represents a domain-
specific impairment. That is, this task produced the largest mean difference in accuracy between groups 
despite its not being the most difficult task, as indicated by the performance of the HOA group. Any 
brain region uniquely recruited for this experimental task would therefore be a candidate weak link in 
ventral stream-dependent processing.  
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Mental rotation is notable for its reliance on processing in the PFC. Cohen et al. (1996) used 
fMRI to examine the brains of healthy participants and observed activation in dorsolateral PFC 
(Brodmann areas 9 and/or 46) in half the individuals tested while performing a mental rotation task 
using Shepard and Metzler stimuli. Further, a meta-analysis of mental rotation studies by Zacks (2008) 
documented seven other studies where mental rotation had produced above-threshold activations in 
the PFC, and traced their overlapping activations to the inferior frontal cortex (Brodmann areas 44 and 
45). However, VWM is also associated with PFC activations. A study by Courtney et al. (1997) used fMRI 
to examine brain activity associated with working memory for faces and identified three prefrontal 
regions with task-driven sustained activations: inferior frontal gyrus, posterior middle frontal gyrus, and 
anterior middle frontal gyrus. Processing in PPC is another hallmark of mental rotation. The same study 
by Cohen et al. (1996) that identified PFC activation during mental rotation also found widely distributed 
task-driven activity in PPC (Brodmann areas 7a and b) across all participants, while a study by Jordan et 
al. (2001) found consistent activation within the intraparietal sulcus while participants performed 
mental rotations of a variety of stimuli, including Shepard and Metzler-type 3D stimuli. However, the 
PPC (in particular the angular gyrus and the posterior supramarginal gyrus) is also the area most strongly 
associated with performance deficits on the BLO test (Tranel et al., 2009). While further research is 
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required to determine the precise extent to which these various task activations coincide, it is at least 
not obvious based on these various findings that either PFC or PPC areas were uniquely recruited for 
Experiment 4. By extension, neither PFC nor PPC damage in individuals with PD provides a conclusive 
explanation for the larger mean difference in accuracy observed for Experiment 4, though both 
possibilities warrant further investigation. 
 If the poor performance by the PD group on the mental rotation task indeed represents a 
qualitatively different processing impairment than has been observed for the other experimental tasks, 
the research discussed thus far would make impairment in motor regions a likely target for 
investigation. Significant task-driven activations in motor areas have been identified in other studies of 
mental rotation using similar stimuli. The meta-analysis of mental rotation experiments by Zacks (2008) 
identified the precentral sulcus as a common site of task-relevant activation during mental rotation. 
Areas in the region identified included the SMA, as well as portions of M1 and the lateral premotor 
cortex. These are areas where processing is known to be impaired in individuals with PD. Specifically, PD 
is associated with decreased activity in the SMA and increased activity in M1 compared with healthy 
individuals of similar age (Haslinger et al., 2001; Rascol et al., 1994; Jenkins et al., 1992), and altered 
signaling between these areas and other areas with which they are connected (Wu et al., 2009). This 
abnormal activity has been shown to be correlated with motor symptoms in PD, with depressed SMA 
activity in particular being associated with akinesia and tremor (Ng et al., 2017; Jenkins et al., 1992). 
Further, mild cognitive impairment and dementia in the later stages of the disease have been associated 
with grey matter hypometabolism and atrophy in the SMA and other precentral motor areas (González-
Redondo et al., 2014). Thus, not only is motor cortical pathology a signature of PD, but this pathology 
has been linked to overt behavioral effects, as well as cognitive effects in more advanced PD.  
If models that characterize supplementary and premotor cortical areas as subserving spatial 
transformation (Cona & Semenza, 2017) and action emulation (Ptak et al., 2017) prove accurate, then it 
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would not be surprising to find that pathology affecting these areas in PD was responsible for impaired 
performance on mental rotation tasks. There are, however, several reasons to be cautious about putting 
too much stock in this interpretation of the results of Experiment 4. First, the abnormal processing 
observed in SMA and M1 in the studies discussed above was relatively normalized through treatment 
with levodopa (Wu et al., 2009; Haslinger et al., 2001), and the motor symptoms related to these 
processing irregularities were improved with dopaminergic medications (Ng et al., 2017; Jenkins et al., 
1992). In contrast, the impairments seen in individuals with PD for mental rotation in Experiment 4 were 
refractory to levodopa treatment. Thus, if impaired functioning in these motor areas contributed to 
poor performance by the PD group, then at minimum the neural mechanisms through which this 
occurred must be different from those that produce motor symptoms. Second, if the reader is not 
persuaded that the group difference observed for the mental rotation task represents a meaningful 
increase over those of the previous four tasks, then strong conclusions based on this interpretation will 
obviously be unpersuasive. Further research, ideally including imaging studies, should be conducted to 
establish the differences in neural activity between mental rotation tasks and more simple 
discrimination tasks. Such research should also further examine what role, if any, DA plays in mental 
rotation impairments in individuals with PD. 
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CHAPTER 9: GENERAL DISCUSSION 
9.1 Summary 
 The purpose of this study was to examine the effects of DA and dopaminergic medications on 
ventral pathway-dependent visual processing in individuals with PD. A variety of visual deficits have 
been reported to accompany PD (see section 1.5), and since the symptomology of PD is largely the result 
of DA dysregulation, it followed that these visual deficits could also be DA-dependent. The mechanisms 
of action for levodopa, a DA precursor medication, have the effect of raising global levels of DA using the 
brain’s own mechanisms for DA synthesis, effectively normalizing DA levels in areas of the brain that are 
DA-deprived so long as the underlying circuitry remains intact. Therefore, observing the performance of 
individuals with PD on cognitive visual tasks both while they were on and off of their levodopa 
medication afforded the opportunity to examine the effects of DA under reasonably controlled 
conditions. Given the nature of PD pathology, and citing previous literature reporting that treatment 
with dopaminergic medications had improved symptoms in lower visual processing, the author 
predicted that participants in the PD group would be impaired relative to their healthy counterparts 
across all experimental tasks, and that administration of levodopa would improve performance to levels 
near or equal to the HOA group. The tasks included in this study were selected for their ability to recruit 
different constellations of cortical processing resources so that any differential response to DA 
manipulation might provide an indication of which brain regions were responsible for performance 
impairments. As anticipated, the PD group performed significantly worse than the HOA group across all 
tasks, providing support for the thesis that ventral pathway-dependent visual processing is typically 
impaired in cases of PD. However, performance deficits in the PD group were unaffected by the 
administration of levodopa, suggesting that mechanisms other than DA depletion were responsible for 
impairments in cognitive vision. Further, given that there were no dramatic changes in mean difference 
between groups across tasks (save, perhaps, the final task), the implications for what specific brain 
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regions or impaired visual processes might be responsible for cognitive visual deficits require a 
somewhat nuanced interpretation. 
 
9.2 Aim 1: 
Aim 1 of the current study was to examine any effect of DA and dopaminergic medications on 
ventral pathway-dependent visual processing. If the visual deficits observed in the various experimental 
tasks had been a result of DA depletion or overdose in individuals with PD, this would have been 
indicated by an interaction between session and group. In the simplest case, performance for the PD 
group would have been altered between sessions as a result of levodopa administration, while no 
analogous change would have been observed in the HOA group. Alternatively, performance by the HOA 
group could have been changed by some additional factor, such as fatigue or practice, while a change in 
performance by the PD group would have differed in degree or in kind. Only the results of Experiment 
2a exhibited this pattern, where the PD group performed worse at abstract object discrimination in the 
afternoon than in the morning, while performance by the HOA group exhibited no significant change 
between sessions.  
Such a finding is consistent with the Dopamine Overdose Hypothesis, which states that 
dopaminergic circuitry that is relatively unaffected in the early stages of PD is adversely affected by the 
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administration of dopaminergic medications because an excess of DA prevents the circuitry from 
functioning properly (Poletti & Bonuccelli, 2013; Graef et al., 2010) (see section 1.6.3). It is at least 
plausible that there is some brain area or process uniquely recruited in the object discrimination task 
that is particularly susceptible to impairment via excess DA, and further research should be conducted 
to examine this possibility. However, given that the three subsequent experimental tasks also require 
some level of discrimination of similarly complex visual stimuli, it seems doubtful that the object 
discrimination task would evince a response to levodopa administration while later tasks would not.  
One thing that stands out about the results of Experiment 2a is that both groups scored at or near 
ceiling on the object discrimination task. Given that cognitive load was likely not a factor driving group 
differences, it is likely that poorer performance by the PD group in the afternoon was caused by 
boredom or fatigue later in the study protocol. This interpretation is bolstered by an effect of session 
observed in Experiment 1, where participants from both groups again scored at or near ceiling and both 
groups performed significantly worse during the afternoon session. The much larger number of trials in 
Experiment 1 (180 compared to 72 in Experiment 2a) may explain why the performance of the HOA 
group also suffered in the afternoon for the line discrimination task. 
 While the finding that poor performance by individuals with PD on ventral pathway-dependent 
visual tasks is unaffected by DA modulation was not predicted, it is not entirely surprising. A number of 
studies have found that cognitive symptoms are less responsive to DA manipulation than motor 
symptoms. A study by Lange et al. (1992) tested individuals with PD both while on their dopaminergic 
medications and following withdrawal for tasks involving attention, memory, learning, and planning. 
These researchers found that DA modulation had no significant effect on performance of spatial or 
pattern recognition memory tasks, simultaneous or delayed match-to-sample tasks, or visual associative 
learning tasks. Indeed, the only cognitive tasks in which accuracy was affected by levodopa withdrawal 
were learning and memory tasks known to be strong indicators of frontal lobe function. Of particular 
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relevance to the current study, Pillon and colleagues (1989) also examined the effects of levodopa in 
cognitive vision in individuals with PD. The experimenters administered a task in which participants were 
instructed to identify common objects depicted in 15 line drawings superimposed on one another and 
found no difference in performance when individuals were in ON-meds vs. OFF-meds states. While the 
15-object task employed in that study also involved ventral pathway-dependent visual processing of 
objects, it differed from the present study in that it involved the retrieval of semantic information about 
target objects, a process previously shown to aid visual processing of object stimuli (Grossman, Galetta, 
& D’Esposito, 1997), possibly by recruiting additional processing resources in the perirhinal cortex 
(Lehky & Tanakam 2016). However, to the best of the author’s knowledge, the observation that 
impaired visual discrimination and spatial transformation of novel objects observed in individuals with 
PD is also refractory to DA therapy is a novel finding of the present study. 
9.3 Aim 2: 
 Aim 2 of the present study was to examine the neural basis of visual impairments observed in 
individuals with PD. In the introduction the author outlined three methods by which abnormal DA 
signaling could produce impairments in cognitive vision. They were as follows: 
 Model 1: Previously characterized PD pathology in the BG may lead to performance deficits for 
visual tasks that recruit processing resources from the striatum. 
 Model 2: PD may lead to impaired dopaminergic signaling in areas of the visual system itself that 
are required for performance of visual tasks. 
 Model 3: Dopaminergic activity within the visual system or other critical areas that is relatively 
spared in the early stages of PD may be disrupted by the dopaminergic medication used to treat 
the disease. 
An additional model was also proposed in which impairments to cognitive vision resulted from 
mechanisms that were not dopaminergic in nature: 
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 Model 4: Visual symptoms may be related to more general brain pathology. 
 If Model 1 or 3 had been correct, we would have predicted some effect of levodopa on task 
performance by the PD group in this study. The basis for Model 1 was the reciprocal connectivity 
between the BG and the ventral visual pathway (Kravitz et al., 2013; Seger et al., 2013), as well as lesion 
studies showing that damage to the BG could disrupt visual discrimination in macaques (Divac et al., 
1967). Model 3 was inspired by the Dopamine Overdose Hypothesis, which was proposed to explain why 
dopaminergic medication had been observed to improve performance on some cognitive tasks for 
individuals with PD while impairing performance on other tasks (Poletti & Bonuccelli, 3013). In either 
case, transitioning from an OFF-meds state to an ON-meds state should have yielded some measurable 
difference in task performance, but this was not observed for this study in a manner that could not be 
better explained by other situational factors.  
 Whether or not the pattern of the results reported here is consistent with Model 2 requires a 
better understanding of the role that DA plays in visual areas than exists in the present literature, as well 
as research into how dopaminergic circuitry in these areas is affected by PD. Model 2 was based on the 
observation that DA receptors are ubiquitous throughout the human visual system at varying levels of 
expression (Hurd, Suzuki, & Sedvall, 2001; Djamgoz & Wagner, 1992). As such, pathology of these 
receptors or deficiency in the levels of DA that they bind could affect visual processing in unpredictable 
ways. Therefore, the diminished task performance observed for the PD group across sessions in this 
study would still be consistent with Model 2 if the dopaminergic circuitry had degraded past the point 
where levodopa could have a therapeutic effect (e.g., if L-DOPA could not be successfully converted to 
DA, or if too few receptors remained intact).  
 In contrast, an effect of group that does not respond to modulation of DA levels is the prediction 
that follows naturally from Model 4. As noted previously, PD is associated with a number of biomarkers 
in addition to DA depletion in the BG. For instance, studies have shown that PD is associated with 
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microstructural changes in both grey and white matter that appear to scale with disease severity 
(Surova et al., 2016), while PD sufficient to produce mild cognitive impairment has been associated with 
hypometabolism and atrophy of both grey and white matter in broadly distributed areas of the brain 
(Gonzalez-Redondo et al., 2014; Agosta et al., 2013). In the case of the visual processing of faces in 
particular, task impairments have been shown to correlate with grey matter loss in an area critical to 
face recognition (Periera et al., 2009). Additionally, researchers have recently reported retinal pathology 
in PD that includes phosphorylated and misfolded α-synuclein (Beach et al., 2014; Bodis-Wollner et al., 
2014). There are thus a variety of candidate mechanisms that could be responsible for observed 
impairments in cognitive vision absent any role of dopaminergic circuitry per se. While the results of this 
study likely rule out several DA-based accounts of how cognitive visual impairments arise in individuals 
with PD, a conclusive account of the mechanisms that are responsible will require further research. 
 This study was also designed to employ tasks that could provide evidence concerning which 
areas the visual system might be the source of any observed visual impairment. Specifically, each of the 
five visual tasks in the current study have been found in previous studies to recruit a slightly different 
constellation of visual areas. If PD pathology had disproportionately affected any of these areas, we 
would have predicted that some appreciable number of individuals in the PD group would have 
performed at or near chance for tasks that required processing in this area while all members of the 
HOA group remained comparatively unaffected. For example, if the PFC deteriorated significantly in PD 
while the ventral visual pathway itself was largely spared, we would predict that members of the PD 
group would perform at or near chance on the VWM and mental rotation tasks while showing little or 
no deficit on the first three tasks. On the other hand, if PD pathology was specific to early visual areas 
such as the retina or V1, we would expect members of the PD group to perform close to chance on all 
five tasks. 
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However, no dramatic drop to chance level was observed for the PD group for any task. Instead, 
the PD group performed significantly worse than the HOA group on all tasks while never showing a 
profound deficit on any one. It is notable that one individual in the PD group scored less than 60% on 
the VWM task. However, this is perhaps not surprising given that both groups performed appreciably 
worse on this task, meaning that an individual in the PD group performing close to chance might be 
predicted based simply on task difficulty. In support of this interpretation, it is notable the mean score 
of the PD group was closer to the HOA group in the VWM task (4.46% mean difference) than in the face 
discrimination task (7% mean difference). In other words, the PD group overall scored closer to chance 
for VWM task, but actually performed closer to baseline than on the previous, easier task. 
 One way to account for the pattern of results observed in this study would be to postulate that 
two regions critical for these tasks were particularly susceptible to PD pathology: one in the early visual 
system and one in motor cortical regions. The former would account for the small but persistent group 
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differences observed in the first four tasks. It may simply be that whatever damage produced the 
impaired fine visual discrimination observed in the line discrimination task produced a similar 
impairment in the discrimination of the object and face stimuli used in this study. In this view, studies 
that have previously reported PD-related impairments in tasks like the FRT may simply have observed a 
generalized discrimination deficit as opposed to one specific to faces. Exactly what impaired process 
might produce this deficit is not clear. Group differences in acuity should theoretically have been 
negligible since both groups were required to have normal or corrected-to-normal vision as judged by a 
relatively recent eye exam (no more than a year prior). Group differences in contrast sensitivity also 
cannot completely account for group differences in task performance because stimuli in the line 
discrimination task were at maximal contrast with their background, though the same was not true for 
the later face and object stimuli. One possibility is that orientation selectivity itself is the root of the 
deficit observed in individuals with PD, resulting from damage anywhere between the retina and early 
cortical visual areas. This is obviously speculation, since the observed pattern of results may be 
consistent with a number of other deficits as well. If this or a similar study were conducted in the future, 
researchers should consider performing an acuity test of all participants during the data collection to 
rule acuity out as a source of impairment for individuals with PD. The design of the current study leaves 
open the possibility that individuals from either group may have misremembered the date of their most 
recent eye appointment, or that their vision may have deteriorated precipitously during the time since 
their checkup. It may also be prudent in the future to add a manipulation that examines the effect of 
varying contrasts, perhaps by including only black-and-white stimuli instead of grey scale, as well as a 
manipulation that examines the effect of spatial frequency, likely through the manipulation of stimulus 
images using software packages with spatial frequency filtering. 
 On the other hand, impairment of the motor cortical regions would account for the increase in 
effect of group observed in Experiment 4. While previous research has indicated that individuals with PD 
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may be impaired relative to their healthy counterparts for mental rotation tasks (see Lee et al., 1998), 
the results of Experiment 4 in this study raise the possibility that the source of this impairment may be 
diminished processing in motor regions of the brain. This position is supported by research suggesting a 
role for motor cortical areas in mental simulation and emulation (Cona & Semenza, 2017; Ptak et al., 
2017) and research indicating that these areas show altered or diminished function in PD (Wu et al., 
2009; Haslinger et al., 2001; Rascol et al., 1994). Researchers wishing to follow up on the present study 
would benefit greatly from neural imaging, and fMRI in particular, to compare activity in M1, SMA, and 
lateral premotor cortices between individuals with PD and their healthy counterparts. This would ideally 
be done while continuing to observe individuals with PD in both ON- and OFF-meds states to determine 
if activity in brain areas recruited for all tasks is affected in ways that may not influence task 
performance (e.g., if DA activity is being normalized in the ON-meds states by some compensatory 
mechanisms). 
9.4 Implications for Individuals with PD 
 Because the results of the current study indicated no changes in ventral pathway-dependent 
vision for individuals with PD between ON- and OFF-meds states, there appears to be no basis for 
concern that administration of levodopa will lead to difficulties in everyday visual processing. There also 
appears to be no basis for concluding that such medication could provide a therapeutic benefit for 
existing cognitive visual impairments. While further research should be conducted to confirm these 
findings, modulation of DA in the brain appears to have no effect on cognitive vision sufficient to impact 
an individual’s activities of daily living. 
 Likewise, performance impairments observed in the PD group in this study are likely insufficient 
to disrupt the daily activities of individuals with PD. While differences between the PD group and their 
healthy counterparts were statistically significant for all experimental tasks, effect sizes were relatively 
small, and the stimuli used were constrained in their design for the purposes of laboratory testing. So, 
104 
 
for instance, poorer performance by individuals with PD on the face discrimination task would not likely 
translate into difficulty learning and remembering novel faces in the real world, where numerous other 
cues to identity are available. Similarly, trials in the VWM task have no obvious analog in everyday 
activities, since individuals are seldom required to make detailed discriminations of complex objects 
following extremely minimal exposure times. Future studies should nevertheless be conducted to 
investigate the ability of individuals with PD to discriminate stimuli under more ecologically valid 
conditions. 
9.5 Conclusion 
This study was designed to investigate the effects of DA and dopaminergic medications on 
impairments to high-level vision in PD. Despite the key role that DA depletion plays in much of the 
pathology of PD, the results of the present study provide strong evidence that modulation of DA levels 
does not improve or impair cognitive vision in individuals with PD. The absence of an effect of levodopa 
in the performance of object and face discrimination tasks, visual working memory tasks, and mental 
rotation tasks represents a novel finding in visual research. Additionally, the finding that impairments to 
complex object discrimination do not appreciably exceed similar impairments in line orientation 
discrimination raises the possibility that high-level visual impairments reported here and elsewhere are 
actually the result of low-level visual impairments, and supports the use of appropriate control tasks 
when examining cognitive vision in PD. Finally, the results of this study provide cursory evidence that 
mental rotation deficits in PD may the result of impaired processing in motor areas of the brain, though 
more research is needed on this topic.  
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